Document:

ex_239175.htm

 

 

Ex. 10.1

EMPLOYMENT AGREEMENT

 

 

This Employment Agreement (the "Agreement"), is effective as of March 31, 2021 (the “Effective Date”), between Aytu BioPharma, Inc., a Delaware corporation headquartered at 373 Inverness Parkway, Suite 206, Englewood, CO 80112 USA, hereinafter referred to as the "Company"), and Richard I. Eisenstadt (“Employee").

 

 

RECITALS 

 

WHEREAS, the Company is a duly organized Delaware corporation, with its principal place of business within the State of Colorado, and is in the business of developing and marketing pharmaceuticals, medical devices, and other healthcare products; and

 

WHEREAS, the Company desires Employee’s experience, skills, abilities, background and knowledge, and is willing to engage Employee’s services on the terms and conditions set forth in this Agreement; and

 

WHEREAS, Employee desires to be in the employ of the Company, and is willing to accept such employment on the terms and conditions set forth in this Agreement.

 

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

 

1.    Employment.

 

(a)    Term. The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the provisions hereof (the “Term”).

 

(b)    Position and Duties. During the Term, the Executive shall serve as the Chief Financial Officer of the Company, and shall have supervision and control over and responsibility for the day-to-day business and affairs of the Company and shall have such other powers and duties as may from time to time be prescribed by the Chief Executive Officer (“CEO”) of the Company, provided that such duties are consistent with the Executive’s position or other positions that he may hold from time to time. The Executive shall devote his full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the CEO, or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not interfere with the Executive’s performance of his duties to the Company as provided in this Agreement. During the Term, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by the Executive to be adverse or antagonistic to the Company, its business or prospects, its financial position, or otherwise or in any company, person or entity that is, directly or indirectly, in competition with the business of the Company or any of its affiliates. This provision shall encompass any advisory boards of which Employee is or becomes a member of during the term hereof. Employee shall provide written disclosure to the Compensation Committee (“Compensation Committee”) of the Company’s Board of Directors (the “Board”) as to all advisory boards on which Employee sits, and will provide the Company with written notice within 10 business days of Executive agreeing to sit on any additional advisory boards. On termination of Executive’s employment, regardless of the reason for such termination, Executive shall immediately (and with contemporaneous effect) resign any directorships, offices or other positions that Executive may hold in the Company or any affiliate, unless otherwise agreed in writing by the parties.

 

2.    Compensation and Related Matters.

 

(a)    Base Salary

 

. During the Term, the Executive’s initial annual base salary shall be four hundred thousand dollars ($400,000.00), less applicable deductions and withholdings. The Executive’s base salary shall be reviewed at least annually by the Compensation Committee or a majority of the independent members of the Board, and the base salary may be increased only by the Compensation Committee or a majority of the independent members of the Board. The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for senior executives.

 

(b)    Bonus Compensation. The Executive shall be eligible for an annual discretionary bonus (hereinafter referred to as the “Bonus”) with a target amount of forty percent (40%) of the Base Salary, subject to standard deductions and withholdings, based on the Compensation Committee’s determination, in good faith, and based upon the Executive’s individual achievement and company performance objectives as set by the Board or the Compensation Committee, of whether the Executive has met such performance milestones as are established for the Executive by the Board or the Compensation Committee, in good faith, in consultation with the Executive (hereinafter referred to as the “Performance Milestones”). The Performance Milestones will be based on certain factors including, but not limited to, the Executive’s performance and the Company’s financial and operational performance. The Executive’s Bonus target will be reviewed annually and may be adjusted by the Board or the Compensation Committee in its discretion, provided however, that the Bonus target may only be reduced upon Employee’s written consent. The Executive must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions hereof. Bonuses shall be paid during the calendar quarter following the calendar quarter for which such Bonus was earned when Performance Milestones are met during a calendar quarter. Fourth quarter Bonuses and Bonuses calculated on the basis of partial Performance Milestone satisfaction shall be paid within 75 days of fiscal year-end.

 

(c)    Signing Bonus. The Executive shall receive a bonus upon signing this agreement in the amount of fifty thousand dollars and zero cents ($50,000.00) less applicable deductions and withholdings (hereinafter referred to as the “Signing Bonus”) to be paid to Executive within thirty days of the closing of the merger transaction with Neos Therapeutics (“Neos Closing”).

 

1

 

 

(d)    Transition Bonus. The Executive shall be eligible for a transition bonus (“Transition Bonus”) in an amount up to one hundred twenty five thousand dollars and zero cents ($125,000.00), less applicable deductions and withholdings, based on CEO’s determination, in his sole discretion, that Executive has successfully accomplished the following Transition Bonus benchmarks between March 19, 2021 and July 1, 2021 (the “Transition Period”): (i) the integration of key accounting functions, as determined by the CEO, including closing of Company’s fiscal Q3 2021 books and timely filing of Company’s consolidated Form 10-Q for fiscal Q3 2021; (ii) satisfactory solicitation, with assistance from and as determined by the Company’s CEO, of new lenders to refinance the “Deerfield Debt”; (iii) the closing of the Rumpus acquisition; (iv) obtaining a signed Contract Manufacturing Organization (“CMO”) contract, acceptable to the Company, with both Adzenys XR-ODT and Cotempla XR-ODT. The Transition Bonus payment, if earned in whole or in part, will be paid to Executive following the Transition Period, and the Executive must be employed on the date the Bonus is awarded to be eligible for the Bonus, subject to the termination provisions herein.

 

(e)    Restricted Stock Unit Grant. The Company shall grant to Executive a restricted stock unit grant of 55,000 shares, which will vest over a (3) year period of employment with the Company beginning with one third (1/3) of the stock vesting on the one-year anniversary of the Effective Date of this Agreement, and the remaining stock vesting in equal quarterly tranches for two years.

 

(f)    Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by him during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its senior executive officers.

 

(g)    Other Benefits. During the Term, the Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans.

 

(h)    Vacations. For the term of this Agreement, Employee shall be entitled to paid time off at the rate of twenty-one (21) days per annum. In accordance with Company policy, unused paid time off may not be carried over from year to year. The Executive shall also be entitled to all paid holidays given by the Company to its executives.

 

3.    Termination. During the Term, the Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

 

(a)    Death. The Executive’s employment hereunder shall terminate upon his death.

 

(b)    Disability. The Company may terminate the Executive’s employment if he is disabled and unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

 

(c)    Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following: (i) the Executive’s material breach of any agreement with the Company, including the Confidentiality and Intellectual Property Agreement, dated March 31, 2021 (the “Confidentiality Agreement”), the provisions of Section 8 of this Agreement, the Code of Conduct or any other material policy that may result in material injury to the Company; (ii) the Executive’s conviction of a felony or any other crime involving dishonesty, breach of trust, moral turpitude, or physical harm to any person (including the Company or any of its employees); (iii) the Executive’s act of fraud or intentional misrepresentation in connection with the Executive’s duties or otherwise in connection with the business of the Company, that may result in material injury to the Company; (iv) the Executive’s material and repeated breach in the performance of duties under this Agreement, including insubordination or failure to implement or follow a lawful policy or directive of the Company, provided that if such failure is curable, it is not cured within 20 days following written notice thereof from the Board; or (v) the Executive’s commission of an act or omission of gross negligence or willful misconduct in the performance of the Executive’s duties that may, in the reasonable determination of the Company, result in material injury to the Company.

 

(d)    Termination Without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.

 

2

 

 

(e)    Termination by the Executive

 

(f)    The Executive may terminate his employment hereunder at any time for any reason, including but not limited to Good Reason. For purposes of this Agreement, “Good Reason” shall mean, without the Executive’s consent, the occurrence of any of the following: (i) the Company materially breaches any term of this Agreement, and such breach causes or is likely to cause material harm to the Executive; (ii) there is a change in the Executive’s responsibilities that represents a material and adverse change from the Executive’s overall responsibilities, taken as a whole; (iii) there is a Change in Control that results in a change in the Executive’s responsibilities that represents a material and adverse change from the Executive’s overall responsibilities, taken as a whole; (iv) the Executive’s Base Salary is substantially reduced or diminished; or (v) the Executive’s place of employment is relocated by the Company more than a 50-mile radius from Grand Prairie, Texas (it being understood and agreed that the Executive may be required to travel in connection with Company business and none of such travel shall constitute or give rise to “Good Reason”). The Executive’s voluntary termination shall be deemed to have occurred for Good Reason for purposes of this Agreement only if (x) the Executive provides written notice to the Company within 30 days after the Executive becomes aware of circumstances giving rise to Good Reason, (y) the Company fails to correct the circumstances giving rise to Good Reason within 30 days following the receipt of such notice (the “Cure Period”) and (z) the Executive resigns within 30 days following the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

 

(g)    Bona Fide Retirement. The Executive may choose to terminate Executive’s employment to effectuate retirement from the pharmaceutical industry (a “Bona Fide Retirement”). A Bona Fide Retirement, for the purposes of this Agreement, meeting certain age and service criteria, voluntarily terminates his employment with the Company and represents and warrants that Executive will not seek or obtain any full-time employment as a senior financial executive in the pharmaceutical industry (full-time employment relating to the discovery, development, and manufacture of drugs and medications by public and private organizations) for a period of at least two years from the date of Executive’s termination (the “Retirement Period”). The Board, in its sole discretion, will determine whether Executive meets certain age and service criteria set by the board, and whether Executive therefore qualifies for a Bona Fide Retirement under this section.

 

(h)    Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.

 

(i)    Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by his death, the date of his death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company under Section 3(d), the date on which a Notice of Termination is given; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) without Good Reason, 30 days after the date on which a Notice of Termination is given, (v) if the Executive’s employment is terminated by the Executive under Section 3(e) with Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period, and (vi) if the Executive’s employment is terminated by Executive for a Bona Fide Retirement, 30 days after the date on which a Notice of Termination is given. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.

 

4.    Compensation Upon Termination.

 

(a)    Termination Generally. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to his authorized representative or estate) (i) any Base Salary earned through the Date of Termination, unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement) and unused vacation that accrued through the Date of Termination on or before the time required by law but in no event more than 30 days after the Executive’s Date of Termination; and (ii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Benefit”).

 

(b)    Termination by the Company Without Cause, by the Executive with Good Reason or for a Bona Fide Retirement. During the Term, if the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates his employment for Good Reason as provided in Section 3(e) or for a Bona Fide Retirement, as provided in Section 3(g), then the Company shall pay the Executive his Accrued Benefit. In addition, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the “Separation Agreement and Release”) and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release:

 

(i)    the Company shall pay the Executive an amount equal to the Executive’s annual Base Salary plus any pro-rated incentive compensation earned (as determined by the Board or the Compensation Committee) but unpaid as of the Date of Termination (the “Severance Amount”). Notwithstanding the foregoing, if the Executive breaches any of the provisions of the Confidentiality Agreement or Section 8 of this Agreement, all payments of the Severance Amount shall immediately cease; and

 

(ii)    Notwithstanding anything to the contrary in the applicable Restricted Stock Agreement, the issued restricted stock will immediately vest following the expiration of the revocation period as set forth in Separation Agreement and Release; and

 

(iii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

 

3

 

 

(iv)    the amounts payable under this Section 4(b) shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2); and

 

(v)    in the event Executive is paid a Severance Amount due to a Bona Fide Retirement in accordance with this Section, but Executive reenters employment in the Pharmaceutical Industry within the Retirement Period, Executive shall be required to return to the Company the entire Severance Amount, and any other payments or benefits received by Executive in accordance with this Section.

 

5.    Change in Control Payment. The provisions of this Section 5 set forth certain terms of an agreement reached between the Executive and the Company regarding the Executive’s rights and obligations upon the occurrence of a Change in Control of the Company. These provisions are intended to assure and encourage in advance the Executive’s continued attention and dedication to his assigned duties and his objectivity during the pendency and after the occurrence of any such event. These provisions shall apply in lieu of, and expressly supersede, the provisions of Section 4(b) regarding severance pay and benefits upon a termination of employment, if such termination of employment occurs within 12 months after the occurrence of the first event constituting a Change in Control. These provisions shall terminate and be of no further force or effect beginning 12 months after the occurrence of a Change in Control.

 

(a)    Change in Control. During the Term, if within 12 months after a Change in Control, the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates his employment for Good Reason as provided in Section 3(e), then, subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release effective all within the time frame set forth in the Separation Agreement and Release,

 

(i)    the Company shall pay the Executive a lump sum in cash in an amount equal to one times the sum of (A) the Executive’s then current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive’s target annual incentive compensation for the then- current year; and

 

(ii)    notwithstanding anything to the contrary in any applicable option agreement or stock-based award agreement, all stock options and other stock-based awards held by the Executive and granted after the Effective Date shall immediately accelerate and become fully exercisable or nonforfeitable as of the Date of Termination; and

 

(iii)    if the Executive was participating in the Company’s group health plan immediately prior to the Date of Termination and elects COBRA health continuation, then the Company shall pay to the Executive a monthly cash payment for 12 months or the Executive’s COBRA health continuation period, whichever ends earlier, in an amount equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company; and

 

(iv)    The amounts payable under this Section 5(a) shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payment shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.

 

For the avoidance of doubt, all stock options and other stock-based awards held by the Executive as of the Effective Date shall be treated as indicated in the applicable award agreements.

 

(b)    Additional Limitation.

 

(i)    Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c).

 

(ii)    For purposes of this Section 5(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.

 

(iii)    The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 5(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

 

4

 

 

(c)    Definitions. For purposes of this Section 5, the following terms shall have the following meanings:

 

“Change in Control” shall mean the consummation of any of the following:

 

(i)    A sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity; or

 

(ii)    A merger, reorganization or consolidation in which the outstanding shares of common stock of the Company are converted into or exchanged for shares of the successor entity and the holders of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the surviving entity immediately upon the completion of such transaction; or

 

 

(iii)    The sale of all or a majority of the common stock of the Company to an unrelated person or entity; or

 

(iv)    Any other transaction in which the holders of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the surviving entity in the transaction immediately upon the completion of such transaction.

 

 

6.    Section 409A.

 

(a)    Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

 

(b)    All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

 

(c)    To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).

 

(d)    The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

 

(e)    The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

 

7.    Intellectual Property. The Executive acknowledges that all discoveries, concepts, ideas, inventions, innovations, improvements, developments, methods, designs, analyses, drawings, reports, patent applications, copyrightable work and mask work (whether or not including any confidential information) and all registrations or applications related thereto, all other proprietary information and all similar or related information (whether or not patentable) which relate to the Company’s or any of its affiliates’ actual or anticipated business, research and development or existing or future products or services and which are conceived, developed or made by the Executive (whether alone or jointly with others) while employed by the Company and its affiliates, whether before or after the date of this Agreement (collectively referred to as “Work Product”), are the property of the Company or such affiliated companies. The Executive shall promptly disclose such Work Product to the Board and, at the Company’s expense, perform all actions reasonably requested by the Board (whether during or after the period of employment) to establish and confirm such ownership (including, without limitation, executing and delivering assignments, consents, powers of attorney and other instruments). The Executive acknowledges that all Work Product shall be deemed to constitute “works made for hire” under the U.S. Copyright Act of 1976, as amended.

 

5

 

 

8.    Confidential Information, Noncompetition and Cooperation

 

The Executive agrees that he continues to be bound by the terms of the Confidentiality Agreement.

 

(a)    The Executive agrees that all property (including, without limitation, all equipment, tangible proprietary information, documents, records, notes, contracts and computer- generated materials) furnished to or created or prepared by the Executive incident to the Executive’s employment belongs to the Company and shall be promptly returned to the Company upon termination of the Executive’s employment.

 

(b)    Upon termination of the Executive’s employment, the Executive shall be deemed to have resigned from any and all offices and directorships then held with the Company and its affiliates. Following any termination of employment, the Executive shall reasonably cooperate with the Company (i) in the winding up of pending work on behalf of the Company and the orderly transfer of work to other employees, and (ii) in the defense of any action brought by any third party against the Company that relates to the Executive’s employment by the Company; provided, that in each case the Company shall reimburse the Executive for any reasonable and documented out-of-pocket fees and expenses incurred by the Executive in connection with such cooperation.

 

 

(c)    The Executive acknowledges that in the course of the Executive’s employment with the Company, the Executive will become familiar with the Company’s and its affiliates’ trade secrets and with other confidential and proprietary information and that the Executive’s services will be of special, unique and extraordinary value to the Company and its affiliates. Therefore, the Executive agrees that the Executive shall not, during the Term and for a period of one (1) year thereafter, directly or indirectly, either for himself or for any other person or entity or otherwise, (i) participate in any business or enterprise (including, without limitation, any division, group or franchise of a larger organization), engaged, anywhere within North America at the time of termination (the “Restricted Territory”), in the business of developing or commercializing controlled release, ion exchange resin based pharmaceutical products, or any other business in which the Executive would be required to employ, reveal or otherwise utilize trade secrets of the Company and its affiliates used prior to termination that may result in a material injury to the Company (with it being understood that the term “participate in” shall include, without limitation, having any direct or indirect interest in any person or entity, whether as a sole proprietor, owner, stockholder, partner, joint venturer, creditor or otherwise, or rendering any direct or indirect service or assistance to any person or entity -whether as a director, officer, manager, supervisor, employee, agent, consultant, advisor or otherwise); provided that, nothing herein shall prohibit the Executive from being a passive owner of not more than two percent (2%) of the outstanding stock of any class of an entity which is publicly traded so long as the Executive has no active participation in the business of such corporation; (ii) induce or attempt to induce any customer, supplier, licensee or other business relation of the Company or any of its subsidiaries to cease doing business with the Company or any such subsidiary or in any way interfere with the relationship between any such customer, supplier, licensee or business relation and the Company and any such subsidiary; or (iii) induce or attempt to induce any employee of the Company or its affiliates to leave the employ of the Company or any such affiliated company, or in any way interfere with the relationship between the Company and any of its affiliates and any employee thereof, or hire or otherwise engage any person who was an employee of the Company or any of its affiliated companies within one year before any such hiring would take place.

 

 

(d)    The Executive agrees that he will not directly or indirectly, individually or in concert with others, make any statement calculated or likely to have the effect of undermining or disparaging the business or the business reputation of the Company or its affiliates or their respective employees, officers, directors, customers, suppliers, successors and assigns, including, without limitation, negative comments about any such person or company, its management methods, policies and/or practices. Notwithstanding the foregoing, nothing herein shall prohibit the Executive from responding accurately and fully to any question, inquiry or request made in connection with any governmental inquiry, investigation, review, audit or proceeding, any legal proceeding or claim (whether in court, arbitration or otherwise) of any nature, or as otherwise required by law.

 

(e)    If, at the time of enforcement of this Section 8, a court holds that the restrictions stated herein are unreasonable under circumstances then existing, the parties hereto agree that the maximum duration, scope or geographical area reasonable under such circumstances shall be substituted for the stated period, scope or area and that the court shall be allowed to revise the restrictions contained herein to cover the maximum duration, scope and area permitted by law. Because the Executive’s services are unique and because the Executive has access to confidential and proprietary information of the Company and its business, the parties hereto agree that money damages would not be an adequate remedy for any breach of Section 8 of this Agreement. Therefore, in the event of a breach or threatened breach of Section 8 of this Agreement, the Company or its successors or assigns may, in addition to other rights and remedies existing in their favor and notwithstanding anything herein to the contrary, apply to any court of competent jurisdiction for specific performance and/or injunctive or other equitable relief in order to enforce or prevent any violations of, the provisions hereof (without posting a bond or other security).

 

(f)    The Executive acknowledges that the provisions of this Section 8 are in consideration of the Executive’s employment with the Company and additional good and valuable consideration as set forth in this Agreement. The Executive agrees and acknowledges that the restrictions contained in Section 8 do not preclude the Executive from earning a livelihood, nor do they unreasonably impose limitations on the Executive’s ability to earn a living. The Executive acknowledges (i) that the business of the Company and its affiliates will be conducted throughout the Restricted Territory, (ii) notwithstanding the state of formation or principal office of the Company and its affiliates, or any of their respective executives or employees (including the Executive), it is expected that the Company will have business activities and have valuable business relationships within its industry throughout the Restricted Territory, and (iii) as part of the Executive’s responsibilities, the Executive may be traveling throughout the Restricted Territory in furtherance of the Company’s and its affiliates’ business and its relationships. The Executive acknowledges that the potential harm to the Company of the non-enforcement of Section 8 outweighs any potential harm to the Executive of its enforcement by injunction or otherwise. The Executive acknowledges that the Executive has carefully read this Agreement and has given careful consideration to the restraints imposed upon the Executive by this Agreement and is in full accord as to their necessity for the reasonable and proper protection of confidential and proprietary information of the Company and its subsidiaries now existing or to be developed in the future. The Executive acknowledges that each and every restraint imposed by this Agreement is reasonable with respect to scope, duration, and geographical area.

 

9.    Arbitration of Disputes. Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executive’s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination whether based on age or otherwise) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of the American Arbitration Association (“AAA”) in accordance with the Employment Dispute Resolution Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. In the event that any person or entity other than the Executive or the Company may be a party with regard to any such controversy or claim, such controversy or claim shall be submitted to arbitration subject to such other person or entity’s agreement. Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. This Section 8 shall be specifically enforceable. Notwithstanding the foregoing, this Section 8 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 9.

 

6

 

 

10.    Consent to Jurisdiction. To the extent that any court action is permitted consistent with or to enforce Section 9 of this Agreement, the parties hereby consent to the jurisdiction of the District Court of of Tarrant County, Texas and the United States District Court for the Northern District of Texas. Accordingly, with respect to any such court action, the Executive (a) submits to the personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.

 

11.    Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, provided that the Confidentiality Agreement remains in full force and effect.

 

 

12.    Withholding. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.

 

13.    Successor to the Executive. This Agreement shall inure to the benefit of and be enforceable by the Executive’s personal representatives, executors, administrators, heirs, distributees, devisees and legatees. In the event of the Executive’s death after his termination of employment but prior to the completion by the Company of all payments due him under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to his death (or to his estate, if the Executive fails to make such designation).

 

14.    Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

 

 

7

 

 

15.    Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

 

16.    Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

 

17.    Notices. Any notice to be given under this Agreement shall be in writing and delivered personally or sent by overnight courier or registered or certified mail, postage prepaid, return receipt requested, addressed to the party concerned at the address indicated below, or to such other address of which such party subsequently may give notice in writing:

 

(a)    If to Employee: To the address specified in the payroll records of the Company.

 

(b)    If to the Company:

 

Aytu BioPharma, Inc.

373 Inverness Parkway

Suite 206

Englewood, Colorado 80112

Any notice delivered personally or by overnight courier shall be deemed given on the date delivered and any notice sent by registered or certified mail, postage prepaid, return receipt requested, shall be deemed given on the date mailed.

 

18.    Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

 

19.    Governing Law. This is a Texas contract and shall be construed under and be governed in all respects by the laws of the State of Texas, without giving effect to the conflict of laws principles of such State. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the Fifth Circuit.

 

20.    Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

 

21.    Successor to Company. The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Company expressly to assume and agree to perform this Agreement to the same extent that the Company would be required to perform it if no succession had taken place. Failure of the Company to obtain an assumption of this Agreement at or prior to the effectiveness of any succession shall be a material breach of this Agreement.

 

22.    Gender Neutral. Wherever used herein, a pronoun in the masculine gender shall be considered as including the feminine gender unless the context clearly indicates otherwise.

IN WITNESS WHEREOF, the parties have executed this Agreement effective on the date and year first above written.

 

AYTU BIOPHARMA, INC.         

By:          

Its:          

 

Executive

 

 

Richard I. Eisenstadt

 

8Exhibit 10.1

 

STOCK PURCHASE AGREEMENT

 

dated as of December 22, 2020

 

among

 

1847 WOLO INC.,

 

WOLO MANUFACTURING CORP.,

 

WOLO INDUSTRIAL HORN & SIGNAL, INC.,

 

BARBARA SOLOW, 

 

AND

 

STANLEY SOLOW

 

 

 

 

     

     

    

 

TABLE
OF CONTENTS

 

	 	Page
	 	 
	ARTICLE I DEFINITIONS	1
	1.1	 Certain Definitions.	1
	ARTICLE II PURCHASE AND SALE OF THE SHARES	6
	2.1	Purchase and Sale of the Shares.	6
	2.2	Adjustments to Purchase Price.	7
	2.3	Closing.	8
	2.4	Transactions to be Effected at the Closing.	9
	ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE SELLER	9
	3.1	Authority and Enforceability.	9
	3.2	Noncontravention.	10
	3.3	The Shares.	10
	3.4	Brokers’ Fees.	10
	ARTICLE IV REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANIES	11
	4.1	Organization, Qualification and Corporate Power; Authority and Enforceability.	11
	4.2	Subsidiaries.	11
	4.3	Capitalization.	11
	4.4	Noncontravention.	12
	4.5	Financial Statements.	13
	4.6	Taxes.	13
	4.7	Compliance with Laws and Orders; Permits.	14
	4.9	Tangible Personal Assets.	14
	4.10	Real Property.	14
	4.11	Intellectual Property.	15
	4.12	Absence of Certain Changes or Events.	16
	4.13	 Contracts.	17
	4.14	 Litigation.	17
	4.15	Employee Benefits.	18
	4.16	Labor and Employment Matters.	18
	4.17	 Environmental.	18
	4.18	Insurance.	19
	4.19	Inventory.	19
	4.20	Notes and Accounts Receivable.	19
	4.21	Powers of Attorney.	19
	4.22	Product Warranty.	19
	4.23	Brokers’ Fees.	19
	4.24	Certain Business Relationships with the Companies.	20
	ARTICLE V REPRESENTATIONS AND WARRANTIES OF THE BUYER	20
	5.1	Organization.	20
	5.2	Authorization.	20
	5.3	Noncontravention.	20

 

    i

     

    

 

	 	Page
	 	 
	ARTICLE VI COVENANTS	21
	6.1	Consents.	21
	6.2	Operation of the Companies’ Business.	21
	6.3	Access.	22
	6.4	Transfer of Cash and Cash Equivalents.	22
	6.5	Notice of Developments.	22
	6.6	No Solicitation.	23
	6.7	Taking of Necessary Action; Further Action; Taxes.	23
	6.8	Covenant not to Compete.	23
	6.9	Financial Information.	24
	6.10	 Disclosure Schedule.	24
	6.11	Accounts Receivable.	24
	6.12	Inventory..	24
	6.13	PPP Loan..	25
	ARTICLE VII CONDITIONS TO OBLIGATIONS TO CLOSE	25
	7.1	 Conditions to Obligation of the Buyer.	25
	7.2	Conditions to Obligation of the Sellers.	27
	ARTICLE VIII TERMINATION; AMENDMENT; WAIVER	28
	8.1	Termination of Agreement.	28
	8.2	Effect of Termination.	28
	8.3	Amendments.	28
	8.4	Waiver.	28
	ARTICLE IX INDEMNIFICATION	29
	9.1	 Survival.	29
	9.2	 Indemnification by Sellers.	29
	9.3	Indemnification by Buyer.	29
	9.4	Indemnification Procedure.	30
	9.5	Failure to Give Timely Notice.	30
	9.6	 Limitation on Indemnification Obligation.	31
	9.7	Exclusive Remedies..	31
	9.8	 Payments.	31
	ARTICLE X MISCELLANEOUS	32
	10.1	 Press Releases and Public Announcement..	32
	10.2	No Third-Party Beneficiaries..	32
	10.3	Entire Agreement..	32
	10.4	Succession and Assignment..	32
	10.5	 Construction.  .	32
	10.6	 Notices.	32
	10.7	Governing Law.	33
	10.8	Consent to Jurisdiction and Service of Process..	34
	10.9	 Headings.	34
	10.10	 Severability.	34
	10.11	 Expenses.	34
	10.12	 Incorporation of Exhibits and Schedules..	34
	10.13	Specific Performance.	34
	10.14	Counterparts.  .	34
	10.15	Seller Representative.	34

 

Disclosure Schedule

 

    ii

     

    

 

STOCK PURCHASE AGREEMENT

 

STOCK PURCHASE AGREEMENT,
dated as of December 22, 2020 (the “Agreement”), among 1847 Wolo Inc.,
a Delaware corporation (the “Buyer”), Wolo Manufacturing Corp.,
a New York corporation and Wolo Industrial Horn & Signal, Inc., a New
York corporation (each, a “Company” and together, the “Companies”), Barbara
Solow and Stanley Solow, as the shareholders of the Companies (each, a
“Sellers” and together, the “Sellers”) and Stanley Solow,
in his capacity as the “Seller Representative” (as defined in Section 10.15). The Buyer, the Companies, the Sellers and the
Seller Representative may each be referred to herein individually as a “Party” or together as the “Parties”.

 

BACKGROUND

 

The Sellers are collectively
the record and beneficial owner of 100% of the issued and outstanding shares of capital stock of the Companies on a fully-diluted basis
(the “Shares”). The Sellers desire to sell all of the Shares to the Buyer, and the Buyer desires to purchase all of
the Shares from the Sellers, upon the terms and subject to the conditions set forth in this Agreement (such sale and purchase of the Shares,
the “Acquisition”).

 

AGREEMENT

 

NOW, THEREFORE, in consideration
of the foregoing premises and the respective representations and warranties, covenants and agreements contained herein, the Parties hereto
agree as follows:

 

ARTICLE I

DEFINITIONS

 

1.1
Certain Definitions.

 

(a)
When used in this Agreement, the following terms will have the meanings assigned to them in this Section 1.1(a):

 

“Action”
means any claim, action, suit, inquiry, hearing, proceeding or other investigation.

 

“Affiliate”
means, with respect to a Person, any other Person that, directly or indirectly, through one or more intermediaries, Controls, is Controlled
by or is under common Control with, such Person. For purposes of this definition, “Control” (including the terms “Controlled
by” and “under common Control with”) means possession of the power to direct or cause the direction of the
management or policies of a Person, whether through the ownership of stock, as trustee or executor, by Contract or otherwise.

 

     

     

    

 

“Benefit Plan”
means any “employee benefit plan” as defined in ERISA Section 3(3), including any (a) nonqualified deferred compensation or
retirement plan or arrangement which is an Employee Pension Benefit Plan (as defined in ERISA Section 3(2)), (b) qualified defined contribution
retirement plan or arrangement which is an Employee Pension Benefit Plan, (c) qualified defined benefit retirement plan or arrangement
which is an Employee Pension Benefit Plan (including any Multiemployer Plan (as defined in ERISA Section 3(37)), (d) Employee Welfare
Benefit Plan (as defined in ERISA Section 3(1)) or material fringe benefit plan or program, or (e) stock purchase, stock option, severance
pay, employment, change-in-control, vacation pay, company award, salary continuation, sick leave, excess benefit, bonus or other incentive
compensation, life insurance, or other employee benefit plan, contract, program, policy or other arrangement, whether or not subject to
ERISA, under which any present or former employee of the Companies have any present or future right to benefits sponsored or maintained
by the Companies or any ERISA Affiliate.

 

“Business”
means the research and development, design, manufacture, assembly, production, marketing, distribution, sale, and repair of horns and
horn accessories, including those for general purpose, automotive, marine, truck, motorcycle and industrial applications as replacement
or specialty accessory purposes, on-board systems and accessories, back-up alarms, warning lights, emergency lights, light bars, hide
away lights, sirens and public address systems, speakers, and other automobile accessories.

 

“Business Day”
means a day other than a Saturday, Sunday or other day on which banks located in New York, NY are authorized or required by Law to close.

 

“Closing Working Capital”
means the Net Working Capital as reflected on the Closing Date Balance Sheet determined in accordance with OCBOA.

 

“Code” means
the Internal Revenue Code of 1986, as amended.

 

“Contract”
means any written agreement, contract, commitment, arrangement or understanding.

 

“ERISA” means
the Employee Retirement Income Security Act of 1974, as amended.

 

“ERISA Affiliate”
means any Person who is, or at any time was, a member of a “controlled group of corporations” together with either Company
within the meaning of Section 414(b) or (c) of the Code and, for the purpose of Section 302 of ERISA and/or Section 412, 4971, 4977, 4980D,
4980E and/or each “applicable section” under Section 414(f)(2) of the Code, within the meaning of Section 412(n)(6) of the
Code that includes, or at any time included, the Companies or any Affiliate thereof, or any predecessor of any of the foregoing.

 

“Escrow Agreement”
means that certain escrow agreement, dated as of the Closing Date, among the Parties and the Escrow Agent, in a form to be agreed among
the Parties and the Escrow Agent.

 

“Escrow Agent”
means JPMorgan Chase Bank.

 

    2

     

    

 

“Exchange Act”
means the Securities Exchange Act of 1934, as amended.

 

“Governmental Entity”
means any entity or body exercising executive, legislative, judicial, regulatory or administrative functions of or pertaining to United
States federal, state or local government or foreign, international, multinational or other government, including any department, commission,
board, agency, bureau, official or other regulatory, administrative or judicial authority thereof.

 

“Indebtedness”
means (a) any obligations relating to indebtedness for borrowed money, (b) any obligations evidenced by bonds, notes, debentures or similar
instruments or (c) the principal or face amount of banker’s acceptances, surety bonds, performance bonds or letters of credit (in
each case whether or not drawn), (c) all obligations to pay the deferred purchase price of property or services, (d) all capital lease
obligations, (e) all obligations or liabilities of others secured by a Lien on any asset, whether or not such obligation or liability
is assumed, (f) all obligations or liabilities of others that are guaranteed, and (g) any other obligations or liabilities which are required
by U.S. Generally Accepted Accounting Principles to be shown as debt on the balance sheet; provided, however, that the PPP Loan shall
not be treated as Indebtedness hereunder in any respect.

 

“Independent Accounting
Firm” means any nationally recognized independent registered public accounting firm which has not represented any of the Parties
or any of their respective Affiliates for the past five years as will be agreed by the Seller Representative and the Buyer in writing.

 

“Inventory Value”
means the amount attributed to the value of the Inventory by the mutual agreement of the Parties pursuant to Section 6.12 of this Agreement.

 

“IRS” means
the Internal Revenue Service.

 

“Knowledge of the Sellers”
or any similar phrase means the actual knowledge of the Seller Representative, in each case without obligation of inquiry.

 

“Law” means
any statute, law, ordinance, rule, regulation of any Governmental Entity.

 

“Liability”
means all indebtedness, obligations and other liabilities and contingencies of a Person, whether absolute, accrued, contingent, fixed
or otherwise, or whether due or to become due.

 

“Lien” means,
with respect to any property or asset, any mortgage, lien, pledge, charge, security interest, hypothecation or other encumbrance in respect
of such property or asset.

 

    3

     

    

 

“Material Adverse Effect”
means any material adverse effect on the assets, properties, condition (financial or otherwise), operations of the Companies and any of
its Subsidiaries, taken as a whole; provided, however, that “Material Adverse Effect” shall not include any event,
occurrence, fact, condition or change, directly or indirectly, arising out of or attributable to: (i) general economic or political conditions;
(ii) conditions generally affecting the industries in which the Company operates; (iii) any changes in financial, banking or securities
markets in general, including any disruption thereof and any decline in the price of any security or any market index or any change in
prevailing interest rates; (iv) acts of war (whether or not declared), armed hostilities or terrorism, or the escalation or worsening
thereof; (v) any action required or permitted by this Agreement or any action taken (or omitted to be taken) with the written consent
of or at the written request of Buyer; (vi) any changes in applicable Laws or accounting rules (including GAAP) or the enforcement, implementation
or interpretation thereof; (vii) the announcement, pendency or completion of the transactions contemplated by this Agreement, including
losses or threatened losses of employees, customers, suppliers, distributors or others having relationships with the Company; or (viii)
any natural or man-made disaster or acts of God (including, without limitation, pandemic).

 

“Minimum Cash Amount”
means $25,000.

 

“Net Working Capital”
means (i) Accounts Receivable; plus (ii) Inventory; plus (iii) prepaid expenses and other current assets, including, but not limited to,
the Minimum Cash Amount; less (iv) current accounts payable, accrued Liabilities and outstanding checks and other current Liabilities. 

 

“Net Working Capital
Target” is equal to $4,250,000.00. 

 

“OCBOA” means
Other Comprehensive Basis of Accounting. The Companies use tax-based accounting on an accrual basis.

 

“Order” means
any award, injunction, judgment, decree, order, ruling, subpoena or verdict or other decision issued, promulgated or entered by or with
any Governmental Entity of competent jurisdiction.

 

“Permit”
means any authorization, approval, consent, certificate, license, permit or franchise of or from any Governmental Entity of competent
jurisdiction or pursuant to any Law.

 

“Permitted Liens” means (a) Liens for current real
or personal property Taxes that are not yet due and payable or that may hereafter be paid without material penalty or that are being contested
in good faith, (b) statutory Liens of landlords and workers’, carriers’ and mechanics’ or other like Liens incurred
in the ordinary course of business or that are being contested in good faith, (c) Liens and encroachments which do not materially interfere
with the present or proposed use of the properties or assets they affect, (d) Liens that will be released prior to or as of the Closing,
(e) Liens arising under this Agreement, (f) Liens created by or through the Buyer, and (g) Liens set forth on Section 3.3(a) of the
Disclosure Schedule.

 

“Person”
means an individual, a corporation, a partnership, a limited liability company, a trust, an unincorporated association, a Governmental
Entity or any agency, instrumentality or political subdivision of a Governmental Entity, or any other entity or body.

 

    4

     

    

 

“PPP Loan”
means that certain loan under the Paycheck Protection Program between JP Morgan Chase Bank and Wolo Manufacturing Corp., in the original
principal amount of $172,350.

 

“Preliminary Working
Capital” means the Net Working Capital as reflected on the Preliminary Balance Sheet, determined in accordance with OCBOA.

 

“Pro Rata Share”
means with respect to Stanley Solow, 50% and with respect to Barbara Solow, 50%.

 

“Representatives”
means, with respect to any Person, the respective directors, officers, employees, counsel, accountants and other representatives of such
Person.

 

“Subsidiary”
means, with respect to any Person, any corporation, partnership, joint venture or other legal entity of which such Person (either alone
or through or together with any other Subsidiary), owns, directly or indirectly, more than 50% of the stock or other equity interests,
the holders of which are generally entitled to vote for the election of the board of directors or other governing body of a non-corporate
Person.

 

“Taxes” means
all federal, state, local and foreign income, profits, franchise, gross receipts, environmental, customs duty, capital stock, severance,
stamp, payroll, sales, transfer, employment, unemployment, disability, use, property, withholding, excise, production, value added, occupancy
and other taxes, tariffs, duties or assessments of any nature whatsoever.

 

“Taxing Authority”
means any Governmental Entity having or purporting to exercise jurisdiction with respect to any Tax.

 

“Tax Returns”
means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule
or attachment thereto, and including any amendment thereof.

 

“Transaction Proposal”
means any unsolicited written bona fide proposal made by a third party relating to (i) any direct or indirect acquisition or purchase
of all or substantially all assets of the Companies, (ii) any direct or indirect acquisition or purchase of a majority of the combined
voting power of the Shares, (iii) any merger, consolidation, business combination, recapitalization, liquidation, dissolution or similar
transaction involving the Companies in which the other party thereto or its stockholders will own 51% or more of the combined voting power
of the parent entity resulting from any such transaction, or (iv) any other transaction that is inconsistent with the intent and purpose
of this Agreement.

 

“Transfer Taxes”
means sales, use, transfer, recording, documentary, stamp, registration and stock transfer Taxes and any similar Taxes.

 

“$” means
United States dollars.

 

    5

     

    

 

(b)
For purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires: (i) the
meaning assigned to each term defined herein will be equally applicable to both the singular and the plural forms of such term and vice
versa, and words denoting any gender will include all genders as the context requires; (ii) where a word or phrase is defined herein,
each of its other grammatical forms will have a corresponding meaning; (iii) the terms “hereof”, “herein”, “hereunder”,
“hereby” and “herewith” and words of similar import will, unless otherwise stated, be construed to refer to this
Agreement as a whole and not to any particular provision of this Agreement; (iv) when a reference is made in this Agreement to an Article,
Section, paragraph, Exhibit or Schedule without reference to a document, such reference is to an Article, Section, paragraph, Exhibit
or Schedule to this Agreement; (v) a reference to a subsection without further reference to a Section is a reference to such
subsection as contained in the same Section in which the reference appears, and this rule will also apply to paragraphs and
other subdivisions; (vi) the word “include”, “includes” or “including” when used in this Agreement
will be deemed to include the words “without limitation”, unless otherwise specified; (vii) a reference to any Party to this
Agreement or any other agreement or document will include such Party’s predecessors, successors and permitted assigns; (viii) a
reference to any Law means such Law as amended, modified, codified, replaced or reenacted as of the date hereof, and all rules and regulations
promulgated thereunder as of the date hereof; and (ix) all accounting terms used and not defined herein have the respective meanings given
to them under OCBOA.

 

ARTICLE II

PURCHASE AND SALE OF THE SHARES

 

2.1
Purchase and Sale of the Shares. Upon the terms and subject to the conditions set forth in this Agreement, at the Closing
the Sellers will sell, transfer and deliver, and the Buyer will purchase from the Sellers, all of the Shares, for an aggregate purchase
price, subject to adjustment as described in Section 2.2, of Seven Million Three Hundred Thousand Dollars ($7,300,000) in cash (the “Purchase
Price”).

 

(a)
At the Closing, the Buyer will deliver to each of the Sellers, in immediately available funds to the account(s) designated by the
Seller Representative prior to the Closing, an amount equal to their respective Pro Rata Share of (i) the Purchase Price, less (ii) the
Escrow Amount (the “Closing Payment”).

 

(b)
At the Closing, the Buyer will deliver an amount equal to the outstanding balance of the PPP Loan as of the Closing Date (the “Escrow
Amount”), which will be delivered to JPMorgan Chase Bank, N.A. (the “Escrow Agent”) for deposit into an escrow
account (the “Escrow Account”) to be established pursuant to the terms of the Escrow Agreement.

 

(c)
At the Closing, the Seller Representative will deliver to the Buyer a certificate or certificates representing the Shares, if certificated,
duly endorsed or accompanied by stock powers duly endorsed in blank.

 

    6

     

    

 

2.2
Adjustments to Purchase Price.

 

(a)
Working Capital Adjustment.

 

(i)
At the Closing, the Sellers shall deliver to the Buyer an unaudited balance sheet of the Companies (the “Preliminary Balance
Sheet”) as at the Closing together with a certificate of the Seller stating that the Preliminary Balance Sheet was prepared
in accordance with OCBOA so as to present fairly in all material respects the financial condition of the Companies as of such date.

 

(ii)
If the Net Working Capital Target exceeds the Net Working Capital as set forth on the Preliminary Balance Sheet, then the Closing
Payment shall be reduced at the Closing by an amount equal to such difference. If the Net Working Capital as set forth on the Preliminary
Balance Sheet exceeds the Net Working Capital Target at Closing, the Closing Payment shall be increased at the Closing by an amount equal
to such difference.

 

(iii)    
As soon as practicable following the Closing Date (but not later than seventy-five (75) days after the Closing Date), the Buyer
shall cause its auditor to prepare and deliver to the Seller Representative an audited balance sheet of the Companies (the “Closing
Date Balance Sheet”) as of the Closing Date. The Closing Date Balance Sheet shall be prepared in accordance with OCBOA in a
manner consistent with the Preliminary Balance Sheet so as to present fairly in all material respects the financial condition of the Companies,
it being understood that, in all circumstances, the same methodology, calculation and principles must be used to calculate each of the
Net Working Capital Target, the Preliminary Working Capital and the Closing Working Capital; provided, however, that the Parties
hereby acknowledge that the Inventory Value (adjusted for inventory sold and inventory received through the closing date and priced at
the price paid by the Company using the Company’s historical inventory pricing methodology) shall be the value attributed to Inventory
for all purposes, including without limitation, the Closing Date Balance Sheet and Closing Working Capital and that under no circumstances
shall there be any reduction to the Inventory Value, the Preliminary Working Capital or the Closing Working Capital on account of any
slow moving, obsolete or other inventory matters unless there is a corresponding dollar for dollar reduction to the Net Working Capital
Target. Unless otherwise consented to by the Sellers, which consent shall not be unreasonably withheld, in the event that the Buyer fails
to deliver to the Closing Date Balance Sheet to the Seller Representative prior to the end of such seventy-five (75) day period, the Net
Working Capital as set forth on the Preliminary Balance Sheet shall be deemed final and conclusive and binding upon the Sellers and the
Buyer as the Closing Working Capital.

 

(iv)
If the Closing Working Capital exceeds the Preliminary Working Capital, then the Buyer (or, at the Buyer’s direction, the
Companies) shall pay promptly (and, in any event, within seven (7) days) to the Sellers an amount in cash that is equal to their respective
Pro Rata Share of such excess. If the Preliminary Working Capital exceeds the Closing Working Capital, then the Sellers shall pay promptly
(and, in any event, within seven (7) days) to the Buyer an amount in cash that is equal to their respective Pro Rata Share of such excess.
Any such adjustment shall be treated as an adjustment to the Purchase Price.

 

    7

     

    

 

(v)
In the event the Seller Representative does not agree with the calculation of Closing Working Capital as reflected on the Closing
Date Balance Sheet, the Seller Representative shall so inform the Buyer in writing within thirty (30) days of the Seller Representative’s
receipt thereof, such writing to set forth the objections of the Seller Representative in reasonable detail. If the Seller Representative
and the Buyer cannot reach agreement as to any disputed matter relating to the Closing Working Capital within thirty (30) days after notification
by the Seller Representative to the Buyer of a dispute, they shall forthwith refer the dispute to an Independent Accounting Firm mutually
agreeable to the Seller Representative and the Buyer for resolution, with the understanding that such firm shall resolve all disputed
items within thirty (30) days after such disputed items are referred to the Independent Accounting Firm. If the Buyer and the Seller Representative
are unable to agree on the choice of an Independent Accounting Firm, they shall select an Independent Accounting Firm by lot (after excluding
their respective regular outside accounting firms). The Sellers, on the one hand, and the Buyer, on the other hand, shall bear one-half
of the costs of such accounting firm. The decision of the accounting firm with respect to all disputed matters relating to the Closing
Working Capital shall be deemed final and conclusive and shall be binding upon the Sellers and the Buyer. In addition, if the Seller Representative
does not object to the Closing Working Capital within the thirty (30) day period referred to above, the Closing Working Capital, as reflected
on the Closing Date Balance Sheet as so prepared, shall be deemed final and conclusive and binding upon the Sellers and the Buyer.

 

(vi)
The Seller Representative shall be entitled to have access to the books and records of the Companies and the Buyer’s work
papers prepared in connection with the Closing Date Balance Sheet and shall be entitled to discuss such books and records and work papers
with the Buyer and those persons responsible for the preparation thereof.

 

(b)
Adjustment for Outstanding Indebtedness. The Closing Payment shall be decreased by the amount of any outstanding Indebtedness
of the Companies existing as of the Closing Date and the deducted amount shall be utilized to pay off such outstanding Indebtedness; provided,
however, that any amounts outstanding as of the Closing Date in respect of the PPP Loan shall remain outstanding and no adjustment to
the Closing Payment shall be made in connection therewith.

 

(c)
Adjustment for Outstanding Cash. The Closing Payment shall be increased by an amount equal to (i) the aggregate amount of
outstanding cash and cash equivalents of the Companies existing as of the Closing Date, less (ii) the Minimum Cash Amount.

 

2.3
Closing. The consummation of the Acquisition (the “Closing”) will take place by the reciprocal delivery
of closing documents by electronic mail, regular mail, fax or any other means mutually agreed upon by the Parties hereto on a date that
is no later than two (2) Business Days immediately following the day on which the last of the conditions to closing contained in Article VII
(other than any conditions that by their nature are to be satisfied at the Closing) is satisfied or waived in accordance with this Agreement
or at such other location or on such other date as the Buyer and the Seller Representative may mutually determine (the date on which the
Closing actually occurs is referred to as the “Closing Date”). Notwithstanding the foregoing, it is the intent of the
Parties that the Closing shall occur on or prior to December 31, 2020. In the event that the Closing occurs following December 31, 2020,
Buyer shall indemnify and hold harmless Sellers for any amounts in respect of Taxes payable by Sellers in connection with the transactions
contemplated by this Agreement that are in excess of the amounts in respect of Taxes that would have been payable by Sellers in connection
with the transactions contemplated by this Agreement if the Closing had occurred on or prior to December 31, 2020.

 

    8

     

    

 

2.4
Transactions to be Effected at the Closing.

 

(a)
At the Closing, the Buyer will (i) pay to each Seller, their respective Closing Payment, adjusted in accordance with subsection
2.2(a)(ii), subsection 2.2(b) and subsection 2.2(c) above, by paying such sum to the Sellers by transfer of immediately available funds
in accordance with instructions provided by the Seller Representative and (ii) deliver to the Sellers all other documents, instruments
or certificates required to be delivered by the Buyer at or prior to the Closing pursuant to Section 7.2 of this Agreement.

 

(b)
At the Closing, the Buyer will deliver the Escrow Amount to the Escrow Agent for deposit into the Escrow Account.

 

(c)
At the Closing, each Seller will deliver to the Buyer (i) a certificate or certificates representing his or her Shares duly endorsed
or accompanied by stock powers duly endorsed in blank and (ii) all other documents, instruments or certificates required to be delivered
by the Sellers at or prior to the Closing pursuant to Section 7.1 of this Agreement.

 

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF THE SELLER

 

Each of the Sellers represents and warrants to the Buyer that each
statement contained in this Article III is true and correct as of the date hereof, except as set forth in the disclosure schedule to be
delivered to the Buyer in accordance with Section 6.11 hereof (the “Disclosure Schedule”). The Disclosure Schedule
has been arranged for purposes of convenience only, in sections corresponding to the Sections of this Article III and Article IV. Each
section of the Disclosure Schedule will be deemed to incorporate by reference all information disclosed in any other section of the Disclosure
Schedule.

 

3.1
Authority and Enforceability. Each Seller has the requisite legal capacity to execute and deliver this Agreement, to perform
such Seller’s obligations hereunder and to consummate the Acquisition and the other transactions contemplated hereby. This Agreement
has been duly executed and delivered by such Seller and, assuming the due authorization, execution and delivery by each other Party hereto,
constitutes a legal, valid and binding obligation of such Seller, enforceable against each Seller in accordance with its terms, except
as limited by (a) bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar Laws relating to creditors’
rights generally and (b) general principles of equity, whether such enforceability is considered in a proceeding in equity or at Law.

 

    9

     

    

 

3.2
Noncontravention.

 

(a) Neither the execution
and the delivery of this Agreement nor the consummation of the Acquisition or the other transactions contemplated by this Agreement will,
with or without the giving of notice or the lapse of time or both, (i) to the Knowledge of the Sellers and assuming compliance with the
filing and notice requirements set forth in Section 3.2(b)(i), violate any Law applicable to such Seller or (ii) violate any Contract
to which such Seller is a party, except to the extent that any such violation would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect.

 

(b)
The execution and delivery of this Agreement by each Seller does not, and the performance of this Agreement by such Seller will
not, require any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity, except for
(i) the filings set forth in Section 3.2(b) of the Disclosure Schedule or (ii) where the failure to take such action would not
reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

3.3
The Shares.

 

(a)
The Sellers holds of record and owns beneficially all of the Shares constituting all of the issued and outstanding shares of capital
stock of the Companies, free and clear of all Liens, other than Permitted Liens.

 

(b)
Except as set forth in this Agreement, no Seller is a party to any Contract obligating a Seller to vote or dispose of any shares
of the capital stock of, or other equity or voting interests in, the Companies.

 

3.4
Brokers’ Fees. Except as set forth in Section 3.4 of the Disclosure Schedule, the Sellers do not have any Liability
to pay any fees or commissions to any broker, finder or agent with respect to this Agreement, the Acquisition or the transactions contemplated
by this Agreement.

 

    10

     

    

 

 ARTICLE IV
 REPRESENTATIONS AND WARRANTIES CONCERNING THE COMPANIES

 

The Seller Representative
represents and warrants to the Buyer that each statement contained in this Article IV is true and correct as of the date hereof, except
as set forth in the Disclosure Schedule.

 

4.1
Organization, Qualification and Corporate Power; Authority and Enforceability.

 

(a)
Each Company is a corporation duly organized, validly existing and in good standing under the Laws of New York, and has all requisite
corporate power and authority, directly or indirectly, to own, lease and operate its properties and assets and to carry on its business
as it is now being conducted. Each Company is duly qualified or licensed as a foreign corporation to do business, and is in good standing,
in each jurisdiction where the character of its properties or assets owned, leased or operated by it or the nature of its activities makes
such qualification or licensing necessary, except where the failure to be so qualified or licensed would not be reasonably expected to
have, individually or in the aggregate, a Material Adverse Effect.

 

(b)
Each Company has the requisite power and authority to execute and deliver this Agreement, to perform its obligations hereunder
and to consummate the transactions contemplated hereby. The execution, delivery and performance by the Companies of this Agreement and
the consummation by the Companies of the transactions contemplated hereby have been duly authorized by all necessary action on the part
of the Companies, and no other action is necessary on the part of the Companies to authorize this Agreement or to consummate the Acquisition
or the other transactions contemplated hereby. This Agreement has been duly executed and delivered by each of the Companies and, assuming
the due authorization, execution and delivery by each other Party hereto, constitutes a legal, valid and binding obligation of the Companies,
enforceable against each of the Companies in accordance with its terms, except as limited by (a) bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other similar Laws relating to creditors’ rights generally and (b) general principles of equity,
whether such enforceability is considered in a proceeding in equity or at Law.

 

4.2
Subsidiaries. The Companies do not have any Subsidiaries.

 

4.3
Capitalization.

 

(a)
The authorized and outstanding capital stock of the Companies is as set forth in Section 4.3(a) of the Disclosure Schedule.
No other capital stock of the Companies are authorized, issued or outstanding.

 

    11

     

    

 

(b)
There are no outstanding options, warrants or other securities or subscription, preemptive or other rights convertible into or
exchangeable or exercisable for any shares of capital stock or other equity or voting interests of the Companies and there are no “phantom
stock” rights, stock appreciation rights or other similar rights with respect to the Companies. There are no Contracts of any kind
to which the Companies are a party or by which the Companies are bound, obligating the Companies to issue, deliver, grant or sell, or
cause to be issued, delivered, granted or sold, additional shares of capital stock of, or other equity or voting interests in, or options,
warrants or other securities or subscription, preemptive or other rights convertible into, or exchangeable or exercisable for, shares
of capital stock of, or other equity or voting interests in, the Companies, or any “phantom stock” right, stock appreciation
right or other similar right with respect to the Companies, or obligating the Companies to enter into any such Contract.

 

(c)
There are no securities or other instruments or obligations of the Companies, the value of which is in any way based upon or derived
from any capital or voting stock of the Companies or having the right to vote (or convertible into, or exchangeable or exercisable for,
securities having the right to vote) on any matters on which the Companies’ stockholders may vote.

 

(d)
There are no Contracts, contingent or otherwise, obligating the Companies to repurchase, redeem or otherwise acquire any shares
of capital stock of, or other equity or voting interests in, the Companies. There are no voting trusts, registration rights agreements
or stockholder agreements to which either of the Companies is a party with respect to the voting of the capital stock of the Companies
or with respect to the granting of registration rights for any of the capital stock of the Companies. There are no rights plans affecting
the Companies.

 

(e)
Except as set forth in Section 4.3(e) of the Disclosure Schedule, there is no Indebtedness of the Companies.

 

4.4
Noncontravention.

 

(a) Neither the execution
and delivery of this Agreement nor the consummation of the Acquisition and the other transactions contemplated by this Agreement will,
with or without the giving of notice or the lapse of time or both, (i) violate any provision of the articles of incorporation or bylaws
(or comparable organization documents, as applicable) of the Companies, (ii) to the Knowledge of the Sellers and assuming compliance with
the filing and notice requirements set forth in Section 4.4(b)(i), violate any Law applicable to the Companies on the date hereof or (iii)
except as set forth in Section 4.4(a) of the Disclosure Schedule, violate any Contract to which the Companies are a party, except
in the case of clauses (ii) and (iii) to the extent that any such violation would not reasonably be expected to have, individually or
in the aggregate, a Material Adverse Effect.

 

(b)
The execution and delivery of this Agreement by the Companies does not, and the performance of this Agreement by the Companies
will not, require any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity, except
for (i) the filings set forth in Section 4.4(b) of the Disclosure Schedule or (ii) where the failure to take such action would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

    12

     

    

 

4.5
Financial Statements. 

 

(a)
Section 4.5(a) of the Disclosure Schedule contains true and complete copies of (i) the unaudited balance sheet of the Companies
as of December 31, 2019 and December 31, 2018 and the related unaudited statements of income and cash flows for the two years ended December
31, 2019 and December 31, 2018 (the “Annual Financial Statements”) and (ii) the unaudited balance sheet of the Companies
as of September 30, 2020 and the related statements of income and cash flows for the nine-month period ended September 30, 2020 (the “Interim
Financial Statements” and, together with the Annual Financial Statements, the “Financial Statements”).

 

(b)
Except for the accruals that are referred to in Section 4.5(b) of the Disclosure Schedule, the Financial Statements: (a)
are prepared from and consistent with such financial statements as have been prepared and used by the Companies in the ordinary course
of managing the Business and measuring and reporting their operating results; (b) are prepared in accordance with OCBOA (except that (i)
purchases and inventories are stated at weighted average cost and (ii) neither Company has made any adjustments pursuant to Section 263A
of the Code) applied on a consistent basis; and (c) fairly present the assets, liabilities, financial position, results of operations,
and cash flows of the Companies as of the dates and for the periods indicated, provided that the Interim Financial Statements do
not have statements of cash flow or footnote disclosures.

 

4.6
Taxes.

 

(a) All material Tax Returns
required to have been filed by the Companies have been filed, and each such Tax Return reflects the liability for Taxes in all material
respects. All Taxes shown on such Tax Returns as due have been paid or accrued.

 

(b) 
To the Knowledge of the Sellers, there is no audit pending against the Companies in respect of any Taxes. There are no Liens on any
of the assets of the Companies that arose in connection with any failure (or alleged failure) to pay any Tax, other than Liens for
Taxes not yet due and payable.

 

(c)
The Companies have withheld and paid or accrued for all material Taxes required to have been withheld and paid or accrued for in
connection with amounts paid or owing to any third party.

 

(d)
The Companies have not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to
a Tax assessment or deficiency.

 

(e)
The Companies are not a party to any Tax allocation or sharing agreement.

 

    13

     

    

 

4.7
Compliance with Laws and Orders; Permits.

 

(a)
The Companies are in compliance with all Laws and Orders to which the business of the Companies are subject, except where such
failure to comply would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

(b)
The Companies owns, holds, possesses or lawfully uses in the operation of its business all Permits that are necessary for it to
conduct its business as now conducted, except where such failure to own, hold, possess or lawfully use such Permit would not reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

4.8
 No Undisclosed Liabilities. The Companies do not have any Liability, except for (i) Liabilities set forth on the Interim
Financial Statements and (ii) Liabilities which have arisen since the date of the Interim Financial Statements in the ordinary course
of business (none of which results from, arises out of, relates to, is in the nature of, or was caused by any breach of contract, breach
of warranty, tort, infringement, or violation of law).

 

4.9
Tangible Personal Assets.

 

(a)
The Companies have good title to, or a valid interest in, all of its tangible personal assets, free and clear of all Liens, other
than (i) Permitted Liens or (ii) Liens that, individually or in the aggregate, do not materially interfere with the ability of the Companies
thereof to conduct its business as currently conducted and do not adversely affect the value of, or the ability to sell, such personal
properties and assets.

 

(b)
The Companies’ tangible personal assets are in good operating condition, working order and repair, subject to ordinary wear
and tear, free from defects (other than defects that do not interfere with the continued use thereof in the conduct of normal operations)
and are suitable for the purposes for which they are currently being used.

 

4.10
Real Property. No Company owns any real property. Section 4.10 of the Disclosure Schedule contains a list of all
leases and subleases (collectively, the “Real Property Leases”) under which the Companies are either lessor or lessee
(the “Real Property”). The Sellers have heretofore made available to the Buyer true and complete copies of each Real
Property Lease. To the Knowledge of the Sellers, (i) all Real Property Leases are valid and binding Contracts of the Companies and are
in full force and effect (except for those that have terminated or will terminate by their own terms), and (ii) neither the Companies
or any other party thereto, is in violation or breach of or default (or with notice or lapse of time, or both, would be in violation or
breach of or default) under the terms of any such Contract, in each case, except where such default would not reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect.

 

    14

     

    

 

4.11
Intellectual Property.

 

(a)
“Intellectual Property” means (i) trade secrets, inventions, confidential and proprietary information, know-how,
formulae and processes, (ii) patents (including all provisionals, reissues, divisions, continuations and extensions thereof) and patent
applications, (iii) trademarks, trade names, trade dress, brand names, domain names, trademark registrations, trademark applications,
service marks, service mark registrations and service mark applications (whether registered, unregistered or existing at common law, including
all goodwill attaching thereto), (iv) copyrights, including copyright registrations, copyright applications and unregistered common law
copyrights; (v) and all licenses for the Intellectual Property listed in items (i) – (iv) above.

 

(b)
Section 4.11(b) of the Disclosure Schedule sets forth a list that includes all material Intellectual Property owned by the
Companies (the “Companies-Owned Intellectual Property”) that is registered or subject to an application for registration
(including the jurisdictions where such Companies-Owned Intellectual Property is registered or where applications have been filed, and
all registration or application numbers, as appropriate).

 

(c)
All necessary registration, maintenance and renewal fees have been paid and all necessary documents have been filed with the United
States Patent and Trademark Office or foreign patent and trademark office in the relevant foreign jurisdiction for the purposes of maintaining
the registered Companies-Owned Intellectual Property.

 

(d)
Except as set forth on Section 4.11(d) of the Disclosure Schedule, (i) the Companies are the exclusive owner of the Companies-Owned
Intellectual Property free and clear of all Liens (other than Permitted Liens); (ii) to the Knowledge of the Sellers no proceedings have
been instituted, are pending or are threatened that challenge the rights of the Companies in or the validity or enforceability of the
Companies-Owned Intellectual Property; (iii) to the Knowledge of the Sellers, neither the use of the Companies-Owned Intellectual Property
as currently used by the Companies in the conduct of the Companies’ business, nor the conduct of the business as presently conducted
by the Companies infringes, dilutes, misappropriates or otherwise violates in any material respect the Intellectual Property rights of
any Person; and (iv) as of the date of this Agreement, the Companies have made no claim of a violation, infringement, misuse or misappropriation
by any Person, of their rights to, or in connection with, the Companies-Owned Intellectual Property.

 

(e)
Except as set forth in Section 4.11(e) of the Disclosure Schedule, the Companies have not permitted or licensed any Person
to use any Companies-Owned Intellectual Property.

 

(f)
Section 4.11(f) of the Disclosure Schedule sets forth a complete and accurate list of all licenses, other than “off
the shelf” commercially available software programs, pursuant to which the Companies licenses from any Person Intellectual Property
that is material to and used in the conduct of the business by the Companies.

 

    15

     

    

 

(g) To the Knowledge of the
Sellers, the Companies are not in default in the performance, observance or fulfillment of any obligation, covenant or condition contained
in any Contract pursuant to which any third party is authorized to use any Companies-Owned Intellectual Property or pursuant to which
the Companies are licensed to use Intellectual Property owned by a third party, except where such default would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

4.12
Absence of Certain Changes or Events. Since the date of the Interim Financial Statements, no event has occurred that has
had, individually or in the aggregate, a Material Adverse Effect. Without limiting the generality of the foregoing, except as set forth
on Section 4.12 of the Disclosure Schedule, since the date of the Interim Financial Statements:

 

(a)
the Companies have not sold, leased, transferred, or assigned any of its material assets, tangible or intangible, other than for
a fair consideration in the ordinary course of business;

 

(b)
the Companies have not entered into any agreement, contract, lease, or license (or series of related agreements, contracts, leases,
and licenses) either involving more than $50,000 or outside the ordinary course of business;

 

(c) no
party (including the Companies) has accelerated, terminated, modified, or cancelled any agreement, contract, lease, or license (or
series of related agreements, contracts, leases, and licenses) involving more than $50,000 to which the Companies are a party or by
which any of them is bound;

 

(d)
the Companies have not imposed any Liens upon any of its assets, tangible or intangible;

 

(e) the
Companies have not made any capital expenditure (or series of related capital expenditures) either involving more than $50,000 or
outside the ordinary course of business;

 

(f) the
Companies have not made any capital investment in, any loan to, or any acquisition of the securities or assets of, any other Person
(or series of related capital investments, loans, and acquisitions) either involving more than $50,000 or outside the ordinary
course of business;

 

(g)
the Companies have not transferred, assigned, or granted any license or sublicense of any rights under or with respect to any material
Intellectual Property;

 

(h)
there has been no change made or authorized in the certificate of incorporation or bylaws of the Companies;

 

(i)
the Companies have not issued, sold, or otherwise disposed of any of its capital stock, or granted any options, warrants, or other
rights to purchase or obtain (including upon conversion, exchange, or exercise) any of its capital stock;

 

    16

     

    

 

(j)
the Companies have not made any loan to, or entered into any other transaction with, any of its directors, officers, and employees
outside the ordinary course of business;

 

(k)
the Companies have not entered into any employment contract or modified the terms of any existing such contract or agreement;

 

(l)
the Companies have not granted any increase in the base compensation of any of its directors, officers, and employees outside the
ordinary course of business;

 

(m)
the Companies have not committed to any of the foregoing.

 

4.13
Contracts.

 

(a)
Except as set forth in Section 4.13(a) of the Disclosure Schedule, as of the date hereof, the Companies are not a party
to or bound by any: (i) Contract not contemplated by this Agreement that materially limits the ability of the Companies to engage or compete
in any manner of the business presently conducted by the Companies; (ii) Contract that creates a partnership or joint venture or similar
arrangement with respect to any material business of the Companies; (iii) indenture, credit agreement, loan agreement, security agreement,
guarantee, note, mortgage or other evidence of indebtedness or agreement providing for indebtedness in excess of $50,000; (iv) Contract
that relates to the acquisition or disposition of any material business (whether by merger, sale of stock, sale of assets or otherwise)
other than this Agreement; and (v) Contract that involves performance of services or delivery of goods or materials by or to the Companies
in an amount or with a value in excess of $50,000 in any 12-month period (which period may extend past the Closing).

 

(b)
The Sellers have heretofore made available to the Buyer true and complete copies of each of the Contracts set forth in Section
4.13(a) of the Disclosure Schedule. To the Knowledge of the Sellers, (i) all such Contracts are valid and binding, (ii) all such Contracts
are in full force and effect (except for those that have terminated or will terminate by their own terms), and (iii) neither any Company
nor any other party thereto, is in violation or breach of or default under (or with notice or lapse of time, or both, would be in violation
or breach of or default under) the terms of any such Contract, in each case, except where such default would not reasonably be expected
to have, individually or in the aggregate, a Material Adverse Effect.

 

4.14
Litigation. Except as set forth in Section 4.14 of the Disclosure Schedule, there is no Action pending or, to the
Knowledge of the Sellers, threatened against the Companies that (a) challenges or seeks to enjoin, alter or materially delay the Acquisition
or (b) would reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect.

 

    17

     

    

 

4.15
Employee Benefits.

 

(a)
Section 4.15(a) of the Disclosure Schedule includes a list of all Benefit Plans maintained or contributed to by the Companies
(the “Companies Benefit Plans”). The Sellers have delivered or made available to the Buyer copies of (i) each Companies
Benefit Plan, (ii) the most recent summary plan description for each Companies Benefit Plan for which such a summary plan description
is required and (iii) the most recent favorable determination letters from the IRS with respect to each Companies Benefit Plan intended
to qualify under Section 401(a) of the Code.

 

(b)
Except as set forth in Section 4.15(b) of the Disclosure Schedule, (i) none of the Companies Benefit Plans is subject to
Title IV of ERISA; (ii) each Companies Benefit Plan that is intended to be qualified under Section 401(a) of the Code is subject to a
favorable determination letter from the IRS and, to the Knowledge of the Sellers, no event has occurred and no condition exists that is
reasonably likely to result in the revocation of any such determination; and (iii) each Companies Benefit Plan is in compliance with all
applicable provisions of ERISA and the Code, except for instances of noncompliance that would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect.

 

4.16
Labor and Employment Matters. Section 4.16 of the Disclosure Schedule sets forth a list of all written employment
agreements that obligate the Companies to pay an annual salary of $50,000 or more and to which the Companies are a party. To the Knowledge
of the Sellers, there are no pending labor disputes, work stoppages, requests for representation, pickets, work slow-downs due to labor
disagreements or any actions or arbitrations that involve the labor or employment relations of the Companies. The Companies are not party
to any collective bargaining agreement.

 

4.17
Environmental. Except (i) as set forth in Section 4.17 of the Disclosure Schedule or (ii) for any matter that would
not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect, (a) the Companies are in compliance with
all applicable Laws relating to protection of the environment (“Environmental Laws”), (b) the Companies possesses and
is in compliance with all Permits required under any Environmental Law for the conduct of its operations and (c) there are no Actions
pending against the Companies alleging a violation of any Environmental Law. No property currently or formerly owned or operated by the
Companies or has been contaminated with any Hazardous Substance in a manner that could reasonably be expected to require remediation or
other action pursuant to any Environmental Law. Neither the Sellers, nor the Companies have received any written notice, demand, letter,
claim or request for information alleging that the Companies or the Sellers are in violation of or liable under any Environmental Law.
For purposes of this Agreement, “Hazardous Substance” means any substance that is: (i) listed, classified, regulated or defined
pursuant to any Environmental Law or (ii) any petroleum product or by-product, asbestos-containing material, polychlorinated biphenyls
or radioactive material.

 

    18

     

    

 

4.18
Insurance. Section 4.18 of the Disclosure Schedule sets forth a list of each insurance policy that covers the Companies
or its businesses, properties, assets, directors, officers or employees (the “Policies”). Such Policies are in full
force and effect in all material respects and the Companies are not in violation or breach of or default under any of its obligations
under any such Policy, except where such default would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect.

 

4.19
Inventory. The inventory of the Companies consists of raw materials and supplies, manufactured and purchased parts, goods
in process, and finished goods (collectively, “Inventory”). Section 4.19 of the Disclosure Schedule sets forth
each item and amount of Inventory owned by the Companies as of the Closing Date. For the avoidance of doubt, neither Sellers nor the Companies
makes any representation or warranty (a) with respect to the price or obsolescence of any of the Inventory owned by the Companies as of
the Closing Date or (b) with respect to whether any amount of Inventory item owned by the Companies as of the Closing Date is excessive.
The Parties agree that the aggregate value of the Inventory shall be equal to the Inventory Value.

 

4.20
Notes and Accounts Receivable. All notes and accounts receivable of the Company are reflected properly on their books and
records, are valid receivables subject to no setoffs or counterclaims, are current and collectible, and will be collected in accordance
with past practice, subject only to the reserve for bad debts set forth on the face of the balance sheet included in the Interim Financial
Statements (rather than in any notes thereto) as adjusted for the passage of time through the Closing Date in accordance with the past
custom and practice of the Company.

 

4.21
Powers of Attorney. There are no outstanding powers of attorney executed on behalf of any of the Companies.

 

4.22
Product Warranty. Section 4.22 of the Disclosure Schedule contains a true, correct, and complete copy of each Company’s
standard written warranty or warranties for sales of its products, and except as expressly set forth therein, there are no warranties,
deviations from standard warranties, or commitments or material obligations with respect to the return, repair, replacement, or re-performance
of products under which any Company has any liability. Section 4.22 of the Disclosure Schedule also contains a description of all
pending warranty claims involving any Company or the Business as of the Closing Date. Other than in the ordinary course of business, none
of the Companies’ products has been the subject of any replacement, field fix, retrofit, modification, or recall campaign. All of
the Companies’ products have been designed, manufactured, labeled, and performed so as to meet and comply with all industry standards
and specifications and all applicable Laws and Orders currently in effect, and have received all governmental approvals necessary to allow
their sale and use.

 

4.23
Brokers’ Fees. Except as set forth in Section 4.23 of the Disclosure Schedule, which such fees shall be paid
prior to or at Closing with the Companies’ cash, the Companies have no Liability to pay any fees or commissions to any broker, finder
or agent with respect to this Agreement, the Acquisition or the transactions contemplated by this Agreement.

 

    19

     

    

 

4.24
Certain Business Relationships with the Companies. Except as set forth in Section 4.24 of the Disclosure Schedule,
no Seller, nor any Affiliate of a Seller, has been involved in any business arrangement or relationship with the Companies within the
past 12 months, and neither the Sellers, nor any Affiliate of the Sellers, owns any asset, tangible or intangible, which is used in the
Business.

 

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF THE BUYER

 

The Buyer represents and warrants
to the Sellers that each statement contained in this Article V is true and correct as of the date hereof.

 

5.1
Organization. The Buyer is a corporation, duly organized, validly existing and in good standing under the laws of the state
of Delaware.

 

5.2
Authorization. The Buyer has the requisite power and authority to execute and deliver this Agreement, to perform its obligations
hereunder and to consummate the transactions contemplated hereby. The execution, delivery and performance by the Buyer of this Agreement,
and the consummation of the transactions contemplated hereby, have been duly authorized by all necessary action, and no other action on
the part of the Buyer is necessary to authorize this Agreement or to consummate the transactions contemplated hereby (other than compliance
with the filing and notice requirements set forth in Section 5.3(b)(i)). This Agreement has been duly executed and delivered by the Buyer
and, assuming the due authorization, execution and delivery by each of the other Parties hereto, constitutes a legal, valid and binding
obligation of the Buyer enforceable against the Buyer in accordance with its terms, except as limited by (a) bankruptcy, insolvency, reorganization,
moratorium, fraudulent conveyance or other similar Laws relating to creditors’ rights generally and (b) general principles of equity,
whether such enforceability is considered in a proceeding in equity or at Law.

 

5.3
Noncontravention.

 

(a)
Neither the execution and the delivery of this Agreement, nor the consummation of the Acquisition and the other transactions contemplated
by this Agreement, will, with or without the giving of notice or the lapse of time or both, (i) violate any provision of the certificate
of incorporation or bylaws (or comparable organization documents, as applicable) of the Buyer, (ii) violate any Law applicable to
the Buyer on the date hereof or (iii) violate any Contract to which the Buyer is a party, except in the case of clauses (ii) and
(iii) to the extent that any such violation would not reasonably be expected to prevent or materially delay the consummation of the Acquisition
and the other transactions contemplated by this Agreement.

 

(b)
The execution and delivery of this Agreement by the Buyer does not, and the performance of this Agreement by the Buyer will not,
require any consent, approval, authorization or Permit of, or filing with or notification to, any Governmental Entity, except for (i)
the filings set forth in Section 5.3(b)(i) or (ii) where the failure to take such action would not reasonably be expected to have, individually
or in the aggregate, a Material Adverse Effect.

 

    20

     

    

 

(c)
Brokers’ Fees. The Buyer has no Liability to pay any fees or commissions to any broker, finder or agent with respect
to this Agreement, the Acquisition or the transactions contemplated by this Agreement that could result in any Liability being imposed
on the Sellers or the Companies.

 

ARTICLE VI

COVENANTS

 

6.1
Consents. The Companies will use its commercially reasonable efforts to obtain any required third-party consents to the
Acquisition and the other transactions contemplated by this Agreement in writing from each Person.

 

6.2
Operation of the Companies’ Business. During the period commencing on the date hereof and ending at the earlier of
the Closing and the termination of this Agreement in accordance with Article VIII, each Company, except (i) as otherwise contemplated
by this Agreement, (ii) as required by applicable Law or (iii) with the prior written consent of the Buyer (which consent will not be
unreasonably withheld or delayed), will use commercially reasonable efforts to carry on its business in a manner consistent with past
practice and not take any action or enter into any transaction that would result in the following:

 

(a)
any change in the articles of incorporation, as amended or bylaws, as amended, of the Companies or any amendment of any material
term of any outstanding security of the Companies;

 

(b)
any issuance or sale of any additional shares of, or rights of any kind to acquire any shares of, any capital stock of any class
of the Companies (whether through the issuance or granting of options or otherwise);

 

(c)
any incurrence, guarantee or assumption by the Companies of any indebtedness for borrowed money other than in the ordinary course
of business in amounts and on terms consistent with past practice;

 

(d) any
change in any method of accounting, accounting principle or accounting practice by the Companies which would reasonably be expected to
have, individually or in the aggregate, a Material Adverse Effect;

 

(e)
except in the ordinary course of business (i) any adoption or material amendment of any Companies Benefit Plan, (ii) any entry
into any collective bargaining agreement with any labor organization or union, (iii) any entry into an employment agreement or (iv) any
increase in the rate of compensation to any employee in an amount that exceeds 10% of such employee’s current compensation; provided,
that the Companies may (A) take any such action for employees in the ordinary course of business or pursuant to any existing Contracts
or Companies Benefit Plans and (B) adopt or amend any Companies Benefit Plan if the cost to such Person of providing benefits thereunder
is not materially increased;

 

    21

     

    

 

(f)
except in the ordinary course of business, any cancellation, modification, termination or grant of waiver of any material Permits
or Contracts to which the Companies are a party, which cancellation, modification, termination or grant of waiver would, individually
or in the aggregate, have a Material Adverse Effect;

 

(g)
any change in the Tax elections made by the Companies or in any accounting method used by the Companies for Tax purposes, where
such Tax election or change in accounting method may have a material effect upon the Tax Liability of the Companies for any period or
set of periods, or the settlement or compromise of any material income Tax Liability of the Companies;

 

(h)
except in the ordinary course of business, any acquisition or disposition of any business or any material property or asset of
any Person (whether by merger, consolidation or otherwise) by a Company;

 

(i)
any grant of a Lien on any properties and assets of a Company that would have, individually or in the aggregate, a Material Adverse
Effect;

 

(j)
any entry into any agreement or commitment to do any of the foregoing.

 

6.3
Access. The Companies will permit the Buyer and its Representatives to have reasonable access at all reasonable times, and
in a manner so as not to interfere with the normal business operations of the Companies, to the premises, properties, books, records (including
Tax records), Contracts and documents of or pertaining to the Companies.

 

6.4
Transfer of Cash and Cash Equivalents. On or prior to the Closing, the Companies and Sellers may transfer, or cause to be
distributed all cash and cash equivalents of the Companies to, among other things, pay any fees owed by Companies to brokers or advisors
(including termination fees under any advisory agreement) and any indebtedness for borrowed money; provided, however, that the Companies
shall have an amount in cash in its corporate bank account and on hand at its store locations at the Closing that is equal to the Minimum
Cash Amount.

 

6.5
Notice of Developments. The Sellers and the Companies will give prompt written notice to the Buyer of any event that would
reasonably be expected to give rise to, individually or in the aggregate, a Material Adverse Effect or would reasonably be expected to
cause a material breach of any of its respective representations, warranties, covenants or other agreements contained herein. The Buyer
will give prompt written notice to the Sellers and the Companies of any event that could reasonably be expected to cause a material breach
of any of its representations, warranties, covenants or other agreements contained herein or could reasonably be expected to, individually
or in the aggregate, prevent or materially delay the consummation of the Acquisition and the other transactions contemplated by this Agreement.
The delivery of any notice pursuant to this Section 6.5 will not limit, expand or otherwise affect the remedies available hereunder (if
any) to the party receiving such notice.

 

    22

     

    

 

6.6
No Solicitation.

 

(a)
Each of the Sellers and the Companies will, and will cause each of their Representatives to, cease immediately any existing discussions
regarding a Transaction Proposal.

 

(b)
From and after the date of this Agreement, without the prior consent of the Buyer, none of the Sellers nor the Companies will,
nor will they authorize or permit any of their respective Representatives to, directly or indirectly through another Person to, (i) solicit,
initiate or encourage (including by way of furnishing information), or take any other action designed to facilitate any inquiries, proposals
or offers from any Person that constitute, or would reasonably be expected to constitute, a Transaction Proposal, (ii) participate
in any discussions or negotiations (including by way of furnishing information) regarding any Transaction Proposal or (iii) otherwise
cooperate in any way with, or assist or participate in, facilitate or encourage, any effort or attempt by any other Person to do or seek
any of the foregoing.

 

(c)
In addition, the Sellers shall immediately communicate to the Buyer the terms of any Transaction Proposal received by any of the
Sellers or the Companies, or any of their Representatives.

 

6.7
Taking of Necessary Action; Further Action; Taxes. Subject to the terms and conditions of this Agreement, each of the Sellers,
the Companies and the Buyer will take all such reasonable and lawful action as may be necessary or appropriate in order to effectuate
the Acquisition in accordance with this Agreement as promptly as practicable. Without limiting the generality of the foregoing, in the
event that any Tax refunds are issued to the Companies that relate to the period prior to the Closing, including without limitation in
connection with the drawbacks described on Section 6.7 of the Disclosure Schedules, the Buyer shall cause the Companies to pay
over such Tax refunds to the Sellers within five (5) days following the receipt by the Companies of the applicable funds.

 

6.8
Covenant not to Compete. For a period of three years from and after the Closing (the “Noncompetition Period”),
each Seller , jointly and severally, shall not engage directly or indirectly in any business that is competitive with the Business within
an area of one hundred miles of any geographic area in which the Business is conducted or which the Buyer plans to conduct the Business
as of the Closing Date; provided, however, that no owner of less than 5% of the outstanding stock of any publicly-traded corporation shall
be deemed to engage solely by reason thereof in any of its businesses. During the Noncompetition Period, the Sellers shall not induce
or attempt to induce any customer, or supplier of the Business to terminate its relationship with the Buyer or any Affiliate of the Buyer
or to enter into any business relationship to provide or purchase the same or substantially the same services as are provided to or purchased
from the Business which might harm the Buyer or any Affiliate of the Buyer. During the Noncompetition Period, the Sellers shall not, on
behalf of any entity other than the Buyer or an Affiliate of the Buyer, hire or retain, or attempt to hire or retain, in any capacity
any Person who is, or was at any time during the preceding twelve (12) months, an employee or officer of the Business. If the final judgment
of a court of competent jurisdiction declares that any term or provision of this Section 6.8 is invalid or unenforceable, the Parties
agree that the court making the determination of invalidity or unenforceability shall have the power to reduce the scope, duration, or
area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with
a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term
or provision, and this Agreement shall be enforceable as so modified after the expiration of the time within which the judgment may be
appealed.

 

    23

     

    

 

6.9
Financial Information. The Sellers shall use reasonable efforts to cooperate with the Buyer and the Buyer’s independent
certified public accounting firm in order to enable the Buyer to create audited financial statements for the two full fiscal years preceding
the Closing Date, by making available the Sellers’ records as they are maintained in the ordinary course of business and answering
reasonable questions.

 

6.10
Post-Closing Access to Books and Records. After the Closing, each Party will afford any other Party, its respective counsel,
accountants and other representatives, during normal business hours, reasonable access to the books, records and other data in such Party’s
possession relating directly or indirectly to the Business with respect to periods prior to the Closing, and the right to make copies
and extracts therefrom at its expense, to the extent such access is reasonably required by the requesting Party for any proper business
purpose, including without limitation, the creation of audited financial statements, the preparation of Tax Returns and litigations. Without
limitation, after the Closing, each Party will make available to any other Party, as reasonably requested, and to any Taxing authority
that is legally permitted to receive the following pursuant to its subpoena power or its equivalent, all books, records and other data
relating to Taxes relating to the Business for all periods prior to or including the Closing and will preserve all such books, records
and other data until the expiration of any applicable statute of limitations for assessment or refund of Taxes or extensions thereof.

 

6.11
Disclosure Schedule. The Sellers have prepared the schedules attached to this Agreement (individually, a “Schedule”
and collectively, the “Disclosure Schedule”) and delivered them to Buyer on the date hereof. Disclosure of any matter,
fact or circumstance in a Schedule to this Agreement shall be deemed to be disclosure thereof for purposes of (a) such Schedule, and (b)
any other Schedule hereto solely to the extent it is reasonably apparent on the face of such disclosure (notwithstanding the absence of
a specific cross reference) that such disclosure is applicable to such other Schedule. and warranties, such language will be disregarded
and be of no force or effect.

 

6.12
Accounts Receivable. The Buyers agree to use commercially reasonable efforts in the ordinary course of business to cause
the Companies to collect all accounts receivable outstanding as of the Closing Date during the period following the Closing Date in accordance
with past practice. In the event that any such accounts receivable are not collected by the conclusion of such period (the “Uncollected
Accounts”), (a) subject to the indemnification provisions of Article IX hereof, the Sellers shall make payment to the Companies
in the amount of such Uncollected Accounts and (b) the Buyers shall cause the Companies to assign such Uncollected Accounts for the benefits
of the Sellers and the Sellers shall have the right to collect such Uncollected Accounts in their sole discretion and for their sole benefit;
provided, that in the event Buyer receives payment in respect of any Uncollected Accounts for which the Sellers have made payment pursuant
to clause (a) above, the Buyer shall within five (5) days of receipt of such monies, pay over such amounts to the Sellers.

 

    24

     

    

 

6.13
Inventory. Prior to the Closing, the Parties shall cooperate to conduct a physical count and valuation of the Inventory
(the “Inventory Count”). In order to facilitate the Inventory Count, the Parties shall engage such professionals and
advisors as they mutually agree and all costs associated with the engagement of such professionals and advisors shall be borne by the
Party incurring such costs. Upon the conclusion of the Inventory Count, the Parties shall agree on the Inventory Value as determined by
the Inventory Count by the mutual execution of Section 6.13 of the Disclosure Schedules.

 

6.14
PPP Loan. Prior to the Closing, the Parties shall cooperate to cause the Companies to apply for forgiveness of the PPP Loan
in accordance with U.S. Small Business Administration Procedural Notice # 5000-20057. At the Closing, the Parties are delivering the Escrow
Amount to Escrow Agent to be held by Escrow Agent in accordance with the terms of this Section 6.14 and the Escrow Agreement. Within five
(5) days following the Closing Date, the Parties shall cooperate to cause the Companies to furnish the following information to Escrow
Agent and the U.S. Small Business Administration: (i) the identity of Buyer; (ii) the ownership percentage(s) of Buyer; (iii) the Tax
ID/ EIN for any owner holding 20% or more of the Companies; and (iv) a copy or summary of terms of the Escrow Agreement. The Escrow Agent
shall deliver from the Escrow Amount to the Sellers any outstanding balance under the PPP Loan that is forgiven by the SBA, and any remaining
PPP Loan amounts that are not forgiven by the SBA shall be paid to the SBA in reduction of the PPP Loan.

 

ARTICLE VII

CONDITIONS TO OBLIGATIONS TO CLOSE

 

7.1
Conditions to Obligation of the Buyer. The obligation of the Buyer to consummate the Acquisition is subject to the satisfaction
or waiver by the Buyer of the following conditions:

 

(a)
The representations and warranties of the Sellers set forth in this Agreement will be true and correct in all respects as of the
date of this Agreement and as of the Closing Date (except to the extent such representations and warranties speak as of another date,
in which case such representations and warranties will be true and correct as of such other date), except where the failure of such representations
and warranties to be so true and correct (without giving effect to any limitation as to “materiality” or “Material Adverse
Effect” set forth therein) does not have, and would not reasonably be expected to have, individually or in the aggregate, a Material
Adverse Effect. The Buyer will have received a certificate signed by the Sellers to such effect.

 

(b)
Each of the Sellers and each of the Companies will have performed all of the covenants required to be performed by it under this
Agreement at or prior to the Closing, except where the failure to perform does not have, and would not reasonably be expected to have,
individually or in the aggregate, a Material Adverse Effect or materially adversely affect the ability of each of the Sellers and the
Companies to consummate the Acquisition or perform its other obligations hereunder. The Buyer will have received a certificate signed
by the Sellers to such effect.

 

(c)
There shall not have been any occurrence, event, incident, action, failure to act, or transaction since the date of the execution
of this Agreement which has had or is reasonably likely to cause a Material Adverse Effect.

 

    25

     

    

 

(d)
All applicable waiting periods (and any extensions thereof) will have expired or otherwise been terminated, and the Parties hereto
will have received all other authorizations, consents and approvals of all Governmental Entities in connection with the execution, delivery
and performance of this Agreement and the transactions contemplated hereby.

 

(e)
No temporary, preliminary or permanent restraining Order preventing the consummation of the Acquisition will be in effect.

 

(f)
Each Party, as appropriate, shall have obtained any required consents, permits, licenses, approvals or notifications of any lenders,
lessors, suppliers, customers or other third parties for which the Buyer will assume responsibility for properly completing any and all
necessary forms required when applying for and securing any necessary transfers.

 

(g)
The Sellers shall have obtained releases of any Liens against any of the assets of the Companies (other than Permitted Liens),
at the Sellers’ expense.

 

(h)
The Buyer shall have received such pay-off letters and releases relating to the indebtedness as it shall have requested, and such
pay-off letters shall be in form and substance satisfactory to it.

 

(i)
The Companies shall have delivered evidence reasonably satisfactory to the Buyer of the Companies’ corporate organization
and proceedings and its existence in the jurisdiction in which it is incorporated, including evidence of such existence as of the Closing.

 

(j)
The Buyer shall have obtained on terms and conditions satisfactory to it all of the financing it needs in order to consummate the
transactions contemplated hereby and fund the working capital requirements of the Companies after the Closing.

 

(k)
The Buyer shall have entered into an employment agreement with the Seller Representative on terms and subject to conditions to
be mutually agreed upon.

 

(l)
All actions to be taken by the Sellers in connection with consummation of the transactions contemplated hereby and all certificates,
opinions, instruments, and other documents required to effect the transactions contemplated hereby will be satisfactory in form and substance
to the Buyer.

 

(m)
The Parties shall have completed the Inventory Count and agreed on the Inventory Value in accordance with Section 6.13 of this
Agreement.

 

    26

     

    

 

7.2
Conditions to Obligation of the Sellers. The obligation of the Sellers to consummate the Acquisition is subject to the satisfaction
or waiver by the Sellers of the following conditions:

 

(a)
The representations and warranties of the Buyer set forth in this Agreement will be true and correct in all respects as of the
date of this Agreement and as of the Closing Date (except to the extent such representations and warranties speak as of another date,
in which case such representations and warranties will be true and correct as of such other date), except where the failure of such representations
and warranties to be so true and correct does not adversely affect the ability of the Buyer to consummate the Acquisition and the other
transactions contemplated by this Agreement. The Sellers will have received a certificate signed on behalf of the Buyer by a duly authorized
officer of the Buyer to such effect.

 

(b)
The Buyer will have performed in all material respects all of the covenants required to be performed by it under this Agreement
at or prior to the Closing except such failures to perform as do not materially adversely affect the ability of the Buyer to consummate
the Acquisition and the other transactions contemplated by this Agreement. The Sellers will have received a certificate signed on behalf
of the Buyer by a duly authorized officer of the Buyer to such effect.

 

(c)
All applicable waiting periods (and any extensions thereof) will have expired or otherwise been terminated and the Parties hereto
will have received all other authorizations, consents and approvals of all Governmental Entities in connection with the execution, delivery
and performance of this Agreement and the transactions contemplated hereby.

 

(d)
No temporary, preliminary or permanent restraining Order preventing the consummation of the Acquisition will be in effect.

 

(e)
Each Party, as appropriate, shall have obtained any required consents, permits, licenses, approvals or notifications of any Governmental
Entities, lenders, lessors, suppliers, customers or other third parties for which the Buyer will assume responsibility for properly completing
any and all necessary forms required when applying for and securing any necessary transfers.

 

(f)
The Seller Representative shall have entered into an employment agreement with the Buyer on terms and subject to conditions to
be mutually agreed upon.

 

(g)
All actions to be taken by the Buyer in connection with consummation of the transactions contemplated hereby and all certificates,
opinions, instruments, and other documents required to effect the transactions contemplated hereby will be satisfactory in form and substance
to the Sellers.

 

(h)
The Parties shall have completed the Inventory Count and agreed on the Inventory Value in accordance with Section 6.13 of this
Agreement.

 

    27

     

    

 

ARTICLE VIII

TERMINATION; AMENDMENT; WAIVER

 

8.1
Termination of Agreement. This Agreement may be terminated as follows:

 

(a)
by mutual written consent of the Buyer and the Sellers at any time prior to the Closing;

 

(b)
by either the Buyer or the Sellers if any Governmental Entity will have issued an Order or taken any other action permanently enjoining,
restraining or otherwise prohibiting the transactions contemplated by this Agreement;

 

(c)
by either the Buyer or the Sellers if the Closing does not occur on or before December 31, 2020; provided that the right
to terminate this Agreement under this Section 8.1(c) will not be available to any Party whose breach of any provision of this Agreement
results in the failure of the Closing to occur by such time;

 

(d)
by the Buyer if the Sellers or the Companies have breached their respective representations and warranties or any covenant or other
agreement to be performed by it in a manner such that the Closing conditions set forth in Section 7.1(a) or 7.1(b) would not be satisfied;
or

 

(e)
by the Sellers if the Buyer has breached its representations and warranties or any covenant or other agreement to be performed
by it in a manner such that the Closing conditions set forth in Section 7.2(a) or 7.2(b) would not be satisfied.

 

8.2
Effect of Termination. In the event of termination of this Agreement by either the Sellers or the Buyer as provided in Section 8.1,
this Agreement will forthwith become void and have no effect, without any Liability (other than with respect to any suit for breach of
this Agreement) on the part of the Buyer, the Companies or the Sellers (or any stockholder, agent, consultant or Representative of any
such Party); provided, that the provisions of Sections 10.1, 10.6, 10.7, 10.8, 10.11, 10.13, 10.15 and this Section 8.2 will
survive any termination hereof pursuant to Section 8.1.

 

8.3
Amendments. This Agreement may not be amended except by an instrument in writing signed on behalf of the Buyer, the Companies
and the Sellers.

 

8.4
Waiver. At any time prior to the Closing, the Buyer may (a) extend the time for the performance of any of the covenants,
obligations or other acts of the Sellers and the Companies or (b) waive any inaccuracy of any representations or warranties or compliance
with any of the agreements, covenants or conditions of the Sellers or any conditions to its own obligations. Any agreement on the part
of the Buyer to any such extension or waiver will be valid only if such waiver is set forth in an instrument in writing signed on its
behalf by its duly authorized officer. At any time prior to the Closing, the Sellers and the Companies, may (a) extend the time for
the performance of any of the covenants, obligations or other acts of the Buyer or (b) waive any inaccuracy of any representations
or warranties or compliance with any of the agreements, covenants or conditions of the Buyer or any conditions to their own obligations.
Any agreement on the part of the Sellers and the Companies to any such extension or waiver will be valid only if such waiver is set forth
in an instrument in writing signed by the Sellers and the Companies. The failure of any Party to this Agreement to assert any of its rights
under this Agreement or otherwise will not constitute a waiver of such rights. The waiver of any such right with respect to particular
facts and other circumstances will not be deemed a waiver with respect to any other facts and circumstances, and each such right will
be deemed an ongoing right that may be asserted at any time and from time to time.

 

    28

     

    

 

ARTICLE IX

INDEMNIFICATION

 

9.1
Survival. The representations and warranties made herein and in any certificate delivered in connection herewith shall survive
for a period fifteen (15) months following the Closing Date, at which time they shall expire; provided, however, that (i) the representations
and warranties set forth in Sections 3.1 (Authority and Enforceability), 3.3 (The Shares), 3.4 (Broker’s Fees), 4.1 (Organization,
Qualification and Corporate Power; Authority and Enforceability), 4.3 (Capitalization), and 4.17 (Environmental) of this Agreement (the
“Fundamental Representations”) shall survive indefinitely and (ii) the representations and warranties in Section 4.6
(Taxes) of this Agreement shall survive until the expiration of the applicable statute of limitations. If written notice of a claim has
been given prior to the expiration of the applicable representations and warranties, then notwithstanding any statement herein to the
contrary, the relevant representations and warranties shall survive as to such claim, until such claim is finally resolved. Unless a specified
period is set forth in this Agreement (in which event such specified period will control), all agreements and covenants contained in this
Agreement will survive the Closing and remain in effect indefinitely.

 

9.2
Indemnification by Sellers. From and after the Closing, the Sellers shall indemnify, defend and save Buyer and its Affiliates,
stockholders, officers, directors, employees, agents and representatives (each, a “Buyer Indemnified Party” and collectively,
the “Buyer Indemnified Parties”) harmless from and against any and all liabilities, deficiencies, demands, claims,
Actions, assessments, losses, costs, expenses, interest, fines, penalties and damages (including fees and expenses of attorneys and accountants
and costs of investigation) (individually and collectively, the “Losses”) suffered, sustained or incurred by any Buyer
Indemnified Party arising out of or otherwise by virtue of: (a) any breach of any of the representations or warranties of the Sellers
or the Companies contained in Article III or IV of this Agreement or (b) the failure of the Sellers to perform any of his or her covenants
or obligations contained in this Agreement.

 

9.3
Indemnification by Buyer. From and after the Closing, the Buyer agrees to indemnify, defend and save the Sellers and to
the extent applicable, the Sellers’ Affiliates, employees, agents and representatives (each, a “Sellers Indemnified Party”
and collectively the “Sellers Indemnified Parties”) harmless from and against any and all Losses sustained or incurred
by any Sellers Indemnified Party arising out of or otherwise by virtue of: (a) any breach of any of the representations and warranties
of Buyer contained in Article V of this Agreement or (b) the failure of Buyer to perform any of its covenants or obligations contained
in this Agreement.

 

    29

     

    

 

9.4
Indemnification Procedure.

 

(a)
If a Buyer Indemnified Party or a Sellers Indemnified Party seeks indemnification under this Article IX, such party (the “Indemnified
Party”) shall give written notice to the other party (the “Indemnifying Party”) of the facts and circumstances
giving rise to the claim. In that regard, if any Action, Liability or obligation shall be brought or asserted by any third party which,
if adversely determined, would entitle the Indemnified Party to indemnity pursuant to this Article IX (a “Third-Party Claim”),
the Indemnified Party shall promptly notify the Indemnifying Party of such Third-Party Claim in writing, specifying the basis of such
claim and the facts pertaining thereto, and the Indemnifying Party, if the Indemnifying Party so elects, shall assume and control the
defense thereof (and shall consult with the Indemnified Party with respect thereto), including the employment of counsel reasonably satisfactory
to the Indemnified Party and the payment of all necessary expenses. If the Indemnifying Party elects to assume control of the defense
of a Third-Party Claim, the Indemnified Party shall have the right to employ counsel separate from counsel employed by the Indemnifying
Party in any such action and to participate in the defense thereof, but the fees and expenses of such counsel employed by the Indemnified
Party shall be at the expense of the Indemnified Party unless (i) the Indemnifying Party has been advised by the Indemnifying Party’s
counsel that a reasonable likelihood exists of a conflict of interest between the Indemnifying Party and the Indemnified Party, or (ii) the
Indemnifying Party has failed to assume the defense and employ counsel; in which case the fees and expenses of the Indemnified Party’s
counsel shall be paid by the Indemnifying Party. All claims other than Third-Party Claims (a “Direct Claim”) may be
asserted by the Indemnified Party giving notice to the Indemnifying Party. Absent an emergency or other extenuating circumstance, the
Indemnified Party shall give written notice to the Indemnifying Party of such Direct Claim prior to taking any material actions to remedy
such Direct Claim.

 

(b)
In no event shall the Indemnified Party pay or enter into any settlement of any claim or consent to any judgment with respect to
any Third-Party Claim without the prior written consent of the Indemnifying Party (which consent shall not be unreasonably withheld, conditioned
or delayed) if such settlement or judgment would require the Indemnifying Party to pay any amount. The Indemnifying Party may enter into
a settlement or consent to any judgment without the consent of the Indemnified Party so long as (i) such settlement or judgment involves
monetary damages only and (ii) a term of the settlement or judgment is that the Person or Persons asserting such Third-Party Claim unconditionally
release all Indemnified Parties from all liability with respect to such claim; otherwise the consent of the Indemnified Party shall be
required in order to enter into any settlement of, or consent to the entry of a judgment with respect to, any Third-Party Claim, which
consent shall not be unreasonably withheld, conditioned or delayed.

 

9.5
Failure to Give Timely Notice. A failure by an Indemnified Party to provide notice as provided in Section 9.4 will
not affect the rights or obligations of any Person except and only to the extent that, as a result of such failure, any Person entitled
to receive such notice was damaged as a result of such failure to give timely notice. Nothing contained in this Section 9.5 shall be deemed
to extend the period for which Sellers’ representations and warranties will survive Closing as set forth in Section 9.1 above.

 

    30

     

    

 

9.6 Limitation on
Indemnification Obligation. Notwithstanding anything in this Agreement to the contrary, the liability of the Sellers to the
Buyer Indemnified Parties with respect to claims for indemnification pursuant to Section 9.2(a) (but not with respect to the
Fundamental Representations for which recovery shall not be so limited) is subject to the following limitations:

 

(a)
The Sellers shall not, in the aggregate, be liable to the Buyer Indemnified Parties for Losses arising under Section 9.2(a) (other
than with respect to acts of fraud or the Fundamental Representations for which recovery shall not be so limited) to the extent that the
amounts otherwise indemnifiable for such breaches exceeds $1,825,000.

 

(b)
The Sellers shall not be liable to the Buyer Indemnified Parties for Losses arising under Section 9.2(a) (other than with respect
to acts of fraud or Fundamental Representations for which recovery shall not be so limited) until and unless the aggregate amounts indemnifiable
for such breaches exceeds $100,000. In the event the Buyer Indemnified Parties’ claim for Losses, in the aggregate, exceed $100,000,
the Buyer Indemnified Parties shall be entitled to the amount of such Losses that exceeds the $100,000 threshold.

 

(c)
The Sellers shall not be liable to the Buyer Indemnified Parties for Losses arising under Section 9.2 unless the claim therefor
is asserted in writing on or prior to the expiration of the applicable representations and warranties.

 

(d)
Losses otherwise subject to indemnity hereunder will be calculated after application of any received insurance proceeds actually
received by the Indemnitee (net of costs of recovery).

 

(e)
In no event shall any Indemnifying Party be liable to any Indemnified Party for any punitive, incidental, consequential, special
or indirect damages, including loss of future revenue or income, loss of business reputation or opportunity relating to the breach or
alleged breach of this Agreement, or diminution of value or any damages based on any type of multiple.

 

9.7
Exclusive Remedies. The Parties acknowledge and agree that their sole and exclusive remedy with respect to any and all claims
for any breach of any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject
matter of this Agreement, shall be pursuant to the indemnification provisions set forth in this Article IX. In furtherance of the foregoing,
each Party hereby waives, to the fullest extent permitted under Law, any and all rights, claims and causes of action for any breach of
any representation, warranty, covenant, agreement or obligation set forth herein or otherwise relating to the subject matter of this Agreement
it may have against the other Parties hereto and their Affiliates and each of their respective Representatives arising under or based
upon any Law, except pursuant to the indemnification provisions set forth in this Article IX. Nothing in this Section 9.7 shall limit
any Person’s right to seek and obtain any equitable relief to which any Person shall be entitled pursuant to Section 10.13.

 

9.8
Payments. Payments of all amounts owing by an Indemnifying Party under this Article IX shall be made promptly upon the determination
in accordance with this Article IX that an indemnification obligation is owing by the Indemnifying Party to the Indemnified Party.

 

    31

     

    

 

ARTICLE X

MISCELLANEOUS

 

10.1
Press Releases and Public Announcement. Neither the Buyer on the one hand, nor the Sellers or the Companies on the other,
will issue any press release or make any public announcement relating to this Agreement, the Acquisition or the other transactions contemplated
by this Agreement without the prior written approval of the other Party; provided, however, that the Buyer may make regulatory filings
referring to this Agreement or attaching a copy hereof as may be required by applicable law.

 

10.2
No Third-Party Beneficiaries. This Agreement will not confer any rights or remedies upon any Person other than the Parties
hereto and their respective successors and permitted assigns.

 

10.3
Entire Agreement. This Agreement (including the Exhibits and the Schedules hereto) constitutes the entire agreement among
the Parties hereto and supersedes any prior understandings, agreements or representations by or among the Parties hereto, written or oral,
to the extent they related in any way to the subject matter hereof.

 

10.4
Succession and Assignment. This Agreement will be binding upon and inure to the benefit of the Parties named herein and
their respective successors and permitted assigns. No Party hereto may assign either this Agreement or any of its rights, interests or
obligations hereunder without the prior written approval, in the case of assignment by the Buyer, by the Sellers, and, in the case of
assignment by the Sellers or the Companies, the Buyer.

 

10.5
Construction. The Parties have participated jointly in the negotiation and drafting of this Agreement, and, in the event
an ambiguity or question of intent or interpretation arises, this Agreement will be construed as if drafted jointly by the Parties, and
no presumption or burden of proof will arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of
this Agreement.

 

10.6
Notices. All notices and other communications that are required or permitted to be given to the Parties under this Agreement
shall be sufficient in all respects if given in writing and delivered in person, by electronic mail, by telecopy, by overnight courier,
or by certified mail, postage prepaid, return receipt requested, to the receiving Party at the address specified below or to such other
address as such Party may have given to the other by notice pursuant to this Section. Notice shall be deemed given on the date of delivery,
in the case of personal delivery, electronic mail, or telecopy, or on the delivery or refusal date, as specified on the return receipt
in the case of certified mail or on the tracking report in the case of overnight courier.

 

If to the Buyer: 1847 Wolo
Inc.

 c/o 1847 Holdings LLC

 590 Madison Avenue, 21st
Floor

 New York, NY 10022

 Attn: Ellery W. Roberts

 Email: eroberts@1847holdings.com

 

    32

     

    

 

with a copy to: Bevilacqua
PLLC

 1050 Connecticut Avenue,
NW

 Suite 500

Washington, DC 20036

Attn: Louis A. Bevilacqua

Email: lou@bevilacquapllc.com

Facsimile: 202-869-0889

 

If to the Companies: Wolo
Manufacturing Corp.

 1 Saxwood Street

Deer Park, NY, 11729 

Attn: Stanley Solow

 Email: stan1952@optonline.net

 

with a copy to:  Meltzer,
Lippe, Goldstein & Breitstone, LLP

 Attn: Ira Halperin , Esq.

  190 Willis Ave

 Mineola, NY 11501

 Facsimile (516) 747-0653

 Email ihalperin@meltzerlippe.com

 

If to the Sellers
or 

Seller Representative: Stanley
Solow

 1 Saxwood Street

Deer Park, NY, 11729 

Attn: Stanley Solow

 Email: stan1952@optonline.net

 

with a copy to: Meltzer,
Lippe, Goldstein & Breitstone, LLP

 Attn: Ira Halperin , Esq.

 190 Willis Ave

 Mineola, NY 11501

 Facsimile (516) 747-0653

 Email ihalperin@meltzerlippe.com

 

Any Party may change the address
to which notices, requests, demands, claims and other communications hereunder are to be delivered by giving the other Parties notice
in the manner set forth herein.

 

10.7
Governing Law. This Agreement will be governed by, and construed in accordance with, the Laws of the State of New York without
giving effect to any choice of Law or conflict of Law provision or rule that would cause the application of the Laws of any jurisdiction
other than the State of New York.

 

    33

     

    

 

10.8
Consent to Jurisdiction and Service of Process. EACH OF THE PARTIES HERETO CONSENTS TO THE JURISDICTION OF ANY STATE OR
FEDERAL COURT LOCATED WITHIN OR HAVING JURISDICTION OVER THE STATE OF NEW YORK, COUNTIES OF NASSAU AND SUFFOLK AND IRREVOCABLY AGREES
THAT ALL ACTIONS OR PROCEEDINGS RELATING TO THIS AGREEMENT, THE ACQUISITION OR THE OTHER TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT MAY
BE LITIGATED IN SUCH COURTS. EACH OF THE PARTIES HERETO ACCEPTS FOR ITSELF AND IN CONNECTION WITH ITS RESPECTIVE PROPERTIES, GENERALLY
AND UNCONDITIONALLY, THE EXCLUSIVE JURISDICTION OF THE AFORESAID COURTS AND WAIVES ANY DEFENSE OF FORUM NON CONVENIENS, AND IRREVOCABLY
AGREES TO BE BOUND BY ANY FINAL AND NONAPPEALABLE JUDGMENT RENDERED THEREBY IN CONNECTION WITH THIS AGREEMENT, THE ACQUISITION OR THE
OTHER TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. EACH OF THE PARTIES HERETO FURTHER IRREVOCABLY CONSENTS TO THE SERVICE OF PROCESS OUT
OF ANY OF THE AFOREMENTIONED COURTS IN ANY SUCH ACTION OR PROCEEDING BY THE MAILING OF COPIES THEREOF BY REGISTERED OR CERTIFIED MAIL,
POSTAGE PREPAID, TO SUCH PARTY AT THE ADDRESS SPECIFIED IN THIS AGREEMENT, SUCH SERVICE TO BECOME EFFECTIVE 15 CALENDAR DAYS AFTER SUCH
MAILING. NOTHING HEREIN WILL IN ANY WAY BE DEEMED TO LIMIT THE ABILITY OF ANY PARTY HERETO TO SERVE ANY SUCH LEGAL PROCESS, SUMMONS, NOTICES
AND DOCUMENTS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW OR TO OBTAIN JURISDICTION OVER OR TO BRING ACTIONS, SUITS OR PROCEEDINGS
AGAINST ANY OTHER PARTY HERETO IN SUCH OTHER JURISDICTIONS, AND IN SUCH MANNER, AS MAY BE PERMITTED BY ANY APPLICABLE LAW.

 

10.9
Headings. The descriptive headings contained in this Agreement are included for convenience of reference only and will not
affect in any way the meaning or interpretation of this Agreement.

 

10.10  
Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future
Law (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable
provision had never comprised a part hereof, (c) the remaining provisions of this Agreement will remain in full force and effect and will
not be affected by the illegal, invalid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid
or unenforceable provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as
similar in terms of such illegal, invalid or unenforceable provision as may be possible.

 

10.11  
Expenses. Except as otherwise provided in this Agreement, whether or not the Acquisition is consummated, all expenses incurred
in connection with this Agreement and the transactions contemplated hereby will be paid by the Party incurring such expenses. As used
in this Agreement, “expenses” means the out-of-pocket fees and expenses of the financial advisor, counsel and accountants
incurred in connection with this Agreement and the transactions contemplated hereby.

 

10.12  
Incorporation of Exhibits and Schedules. The Exhibits and Schedules identified in this Agreement are incorporated herein
by reference and made a part hereof.

 

10.13  
Specific Performance. The Parties hereto agree that irreparable damage would occur in the event that any provision of this
Agreement was not performed in accordance with the terms hereof and that the Parties will be entitled to specific performance of the terms
hereof in addition to any other remedy at Law or equity.

 

10.14  
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including
pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

10.15  
Seller Representative. The Sellers hereby appoint and constitute Stanley Solow as the “Seller Representative”
hereunder, to exercise the powers on behalf of the Sellers set forth in this Agreement, and Stanley Solow hereby accepts such appointment.
The Sellers, by execution of this Agreement, each hereby constitute and appoint the Seller Representative his or her true and lawful attorney
in fact, with full power in his or her name and on his or her behalf, in the absolute discretion of Seller Representative: (i) to act
on behalf of the Sellers according to the terms of this Agreement; (ii) to give and receive notices on behalf of the Sellers; (iii) to
act on behalf of the Sellers in connection with any matter as to which Sellers are an “Indemnified Party” or “Indemnifying
Party” under Article IX; and (iv) in general, to do all things and to perform all acts, including executing and delivering all agreements,
certificates, receipts, instructions, and other instruments contemplated by or deemed advisable in connection with this Agreement. This
power of attorney, and all authority hereby conferred, is granted subject to the interests of Buyer hereunder and in consideration of
the mutual covenants and agreements made herein and will be irrevocable and will not be terminated by any act of the Sellers or by operation
of Law or by the occurrence of any other event. All action taken by Seller Representative hereunder will be final and binding upon the
Sellers. The Sellers agree to hold the Seller Representative free and harmless from any and all loss, damage, or liability that they,
or any one of them, may sustain as a result of any action taken in good faith by Seller Representative hereunder.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

    34

     

    

 

IN WITNESS WHEREOF, the Parties
hereto have caused this Agreement to be duly executed as of the date first above written.

 

	 	BUYER:
	 	 
	 	1847 Wolo Inc.
	 	 
	 	By:	                                        
	 	Name:	 
	 	Title:	 
	 	 
	 	COMPANIES:
	 	 
	 	WOLO MANUFACTURING CORP.
	 	 
	 	By:	  
	 	Name:	 Stanley Solow
	 	Title:	 President and CEO
	 	 
	 	WOLO INDUSTRIAL HORN & SIGNAL, INC.
	 	 
	 	By:	 
	 	Name:	 Stanley Solow
	 	Title:	 President and CEO
	 	 
	 	SELLERS:
	 	 
	 	By:	 
	 	Name: 	Stanley Solow
	 	 
	 	By:	 
	 	Name: 	Barbara Solow
	 	 
	 	SELLER REPRESENTATIVE:
	 	 
	 	By:	 
	 	Name: 	Stanley Solow

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]